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ABSTRACT 
 
JUANLI GUO: The involvement of Wnt signaling in osteoblastic cell behavior 
(Under the direction of Dr. Lyndon F. Cooper) 
 
 Wnt (wingless and int-related proteins) are a family of secreted cysteine-rich 
glycoproteins, expressed in a variety of tissues in developing embryos and adult tissues, thought 
to be implicated in oncogenesis, embryonic development, and regeneration of adult tissues. In our 
study, Wnt5a was found to be one of the predominant Wnts that are expressed during osteoblastic 
differentiation of hMSCs in vitro and during hMSC-directed ectopic osteogenesis in the severe 
combined immunodeficient (SCID) mouse host.  RT-PCR further revealed that hWNT5A and its 
receptor Frizzled family member 5 (hFZD5) was up-regulated during osteoblastic differentiation. 
The function of Wnt5a was further evaluated using knock-out model. Wnt5a-/- calvarial cells 
showed significantly slower cell proliferation when compared to Wnt5a+/- and wild type cells. 
Gene expression profiles of the Wnt5a-/- calvarial cells as compared to wild type cells were 
evaluated using microarray analysis. 255 genes exhibited at least 2-fold changes in expression. In 
addition, genes including Runx2, osterix, and alkaline phosphatase (ALP) were shown to be 
down-regulated in Wnt5a-/- cells. The results suggested that Wnt5a plays a role in osteogenesis.  
 The low density lipoprotein receptor-related protein 5 (LRP5) is a key determinant of 
bone mass. In this study, constitutively active LRP5 was constructed by deletion of the 
extracellular domain of LRP5 (LRP5ΔN). The LRP5 signaling and the effects of an intracellular 
domain single nucleotide polymorphism (SNP: p.V1525A) on osteoblast differentiation and 
 ii
mineralization were studied. Expression of LRP5ΔN-V, which carries the allele p.1525V, induced 
higher β-catenin/TCF-LEF activity compared to LRP5ΔN-A, which carries the allele p.1525A. In 
a yeast two-hybrid assay, LRP5ΔN-V also demonstrated a stronger interaction with AXIN than 
LRP5ΔN-A. Expression of either of the alleles did not change cell proliferation. However, cells 
expressing LRP5ΔN-V showed increased ALP activity and bone nodule formation compared to 
cells transfected with empty vector or LRP5ΔN-A after osteogenic supplement (OS) treatment. 
Cells expressing LRP5ΔN-V revealed significantly increased bone sialoprotein (BSP) and 
osteocalcin (OCN) mRNA levels with OS treatment. LRP5ΔN-V expressing cells demonstrated 
positive interaction with BMP-2 signaling of transcription at the SBE-luc promoter. The mRNA 
levels of Runx2 and Osterix were not affected by this SNP. 
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CHAPTER I 
 
INTRODUCTION 
 
I. Osteoblast differentiation and its regulation 
 I.a. Introduction 
 Osteoblasts along with chondrocytes, myoblasts and adipocytes arise from common 
progenitors known as pluripotent mesenchymal stem cells. There are two different manners 
during skeletogenesis: intramembranous ossification and endochondral ossification. In the 
process of endochondral ossification, condensed mesenchymal cells first form cartilage, which is 
then replaced by mineralization and forming bone. Most of the bones, including axial and 
appendicular skeletons, are formed in this fashion. In the case of intramembranous ossification, 
osteogenesis directly occurs in the condensed mesenchymal cells. Flat bones of the skull, part of 
the clavicle, and additional periosteal bone of the long bone are formed in this fashion. 
 Osteoblastic differentiation is a complex process involving a variety of different signaling 
molecules. Prominent among them are the BMP-mediated signals, runt-related transcription 
factor 2 (Runx2) regulation of gene expression and osterix directed transcription (Ducy et al 1997; 
Komori et al 1997; Nakashima et al 2002; Otto et al 1997; Skillington Choy and Derynck 2002).  
In addition, numerous growth factors as well as systemic hormones play important roles in the 
definition of the osteoblast phenotype (Aubin and Bonnelye 2000). Developmental signaling in 
limb as well as craniofacial development invokes signals from a wider range of molecules 
including msh homeobox (MSX), distal-less homeobox (DLX) and Wnt family members 
(Carlson Bryant and Gardiner 1998; Church and Francis-West 2002; Robledo et al 2002). 
 To investigate the roles of local factors in osteoblast differentiation and bone formation, it 
is very important to establish in vitro culture systems that simulate the different stages of 
osteogenesis. Table 1 summarizes several cell lines that are commonly used for investigating 
osteoblast differentiation in vitro (Yamaguchi Komori and Suda 2000). Genetic studies in mice 
have also provided new insights into the transcriptional regulation of osteoblast differentiation.  
Table 1. Characteristics of cells useful for analyzing osteoblast differentiation in vitro 
(Yamaguchi Komori and Suda 2000) 
Name of cells Origin Characteristics 
C3H10T1/2 Early mouse embryo A pluripotent cell line, which 
can differentiate into 
osteoblasts, chondrocytes, 
myotubes, and adipocytes 
ROB-C26 Newborn rat calvaria An osteoblast precursor cell 
line, which is capable of 
differentiating into myotubes 
and adipocytes 
MC3T3-E1 Calvaria of a late stage 
mouse embryo 
A monopotential cell line, 
which can only differentiate 
into osteoblast lineage cells 
ST2 Bone marrow of adult 
mouse 
A bone marrow stromal cell 
line that can differentiate into 
osteoblasts 
C2C12 A subclone isolated from 
parental C2 myoblasts, 
which were established from 
the regenerating thigh 
muscle of an adult mouse 
A myogenic cell line with 
characteristics of satellite 
cells. This cell line 
differentiates into osteoblasts 
on treatment with BMPs 
Calvaria-derived primary 
osteoblastic cells 
Calvaria from late embryos 
or newborn rats 
Primary culture of osteoblastic 
cells. These cells are a mixed 
population of several cell 
types, but retain various 
osteoblastic phenotypes 
including bone-nodule 
formation 
Human mesenchymal 
stem cells 
Human adult bone marrow Bone marrow stromal cells 
that can differentiate into 
osteoblast, chondrocytes, 
myotubes, and adipocytes 
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 I.b. Regulation of osteoblast differentiation by bone morphogenetic proteins (BMPs) 
 BMPs were originally identified as proteins capable of inducing ectopic bone formation 
upon implantation into muscular tissues (Urist 1965). Currently, more than 20 BMPs have been 
cloned. They belong to the transforming growth factor-β (TGF-β) superfamily and regulate early 
embryogenesis and subsequent organogenesis. During embryonic life, BMPs regulate 
neurogenesis and hematopoiesis and induce somite formation. In the limb bud, they interact with 
fibroblast growth factor (FGF) 4 and Sonic Hedgehog (Shh), reducing limb bud expansion and 
inducing the formation of chondrocyte and osteoblasts precursors (Kishigami and Mishina 2005). 
After birth, BMPs play a role in the maintenance of bone mass. They induce the differentiation of 
marrow stromal cells toward the osteoblastic lineage, therefore increasing the pool of mature 
bone forming cells, and enhance the differentiated function of osteoblasts.  
 The effects of BMP in bone tissue have been confirmed by various mouse models. Global 
knock-outs models of BMPs have furthered the understanding of BMP action in embryogenesis, 
but severe disturbances in organ development and frequent lethality have not allowed the 
determination of BMP effects in bone after birth (Daluiski et al 2001; Luo et al 1995; Solloway et 
al 1998; Winnier et al 1995; Zhang and Bradley 1996). The analysis of BMP activities in skeletal 
tissue of adult animals has become possible recently through the engineering of tissue-specific 
genetic mouse models. Bmp-2/4 conditional knock-out mice in which Bmp-2/4-loxP mice were 
crossed with Paired-related homeobox (Prx)-1-Cre transgenics to delete the bmp-2 and bmp-4 
genes in the mesenchyme of the first branchial arches and in the limb mesoderm, show severe 
defects in membranous bone ossification and absence of osteoblast differentiation. Accordingly, 
BMP-4loxP mice crossed with collagen type I-Cre transgenics, to obtain an osteoblast targeted 
deletion of bmp 4, display defects in skeletal growth and postnatal bone formation 
(Bandyopadhyay et al 2006). 
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 Like the other members of TGF-β family, BMPs signals through the combination 
activation of two types of serine-threonine kinase receptors termed BMP type I (BMPR-I) and 
type II receptors (BMPR-II). Three kinds of BMPR-Is, including activin receptor-like kinase 2 
(ALK2), ALK3/BMPR-IA, and ALK6/BMPR-IB, and three distinct BMPR-IIs, including 
BMPR-II, activin type IIA (ActRIIA), and activin type IIB (ActRIIB), have been identified as 
receptors for BMP ligands. 
 Smads are the major signal transducers for BMP signal. Upon ligand stimulation and 
BMPR-II activation, BMPR-I phosphorylates receptor-regulated Smads (R-Smads), which form a 
complex with common-partner Smads (Co-Smads). The R-Smads/Co-Smads complexes then 
translocate into nucleus and regulate transcription of target genes, by interacting with various 
transcription factors and transcriptional co-activators or co-repressors. There are 8 Smads proteins 
identified in mammals, among which Smad1, Smad5, and Smad8 are R-Smads activated by 
BMPR-Is (BR-Smads). Smad2 and Smad3 are activated by activin and TGF-β type I receptors 
(AR-Smads). Smad4 is the Co-Smad shared by BMP and TGF-β/activin signaling pathways. 
Smad6 and Smad7 are served as inhibitory Smads (I-Smads), which negatively regulate the 
signaling of R-Smads/Co-Smads complex.  
 Smad3 and Smad4 directly bind to Smad binding elements (SBE, 5’-AGAC-3’ or 5’-
GTCT-3’ sequence).  Smad2 does not bind to SBC directly, but by forming a complex with 
Smad3 and Smad4, it indirectly binds to SBE. Thus SBE is responsive to Activin or TGF-β 
signaling (Dennler et al 1998; Zawel et al 1998). It has been implied that BR-Smads only weakly 
interact with SBE, instead they bind to 5’-GCCGnCGC-3’ (GC-rich) sequences upon BMP 
stimulation in the presence of Smad4 (Ishida et al 2000; Kusanagi et al 2000). The SBE reporter 
constructs and the BRE (BMP responsive element) reporter constructs have been widely used in 
investigation of signaling related to TGF-β superfamily. In general, if some ligands activate AR-
Smads and transduce Activin/TGF-β like signal, they activate the promoter-reporter constructs 
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containing the 5’-AGAC-3’ sequence. If some ligands activate BR-Smads and transmit BMP-like 
signals, they activate the reporters that containing multiple repeats of GC-rich motifs. However, it 
is not necessarily true to state that BR-Smads bind to BRE, whereas AR-Smads bind to SBE. 
Smad1 has also been shown to bind to canonical SBE in the BMP-responsive region of Xenopus 
Vent-2 promoter (Hata et al 2000).   
 Activated RSmad-Smad4 complexes selectively regulate target gene expression by 
association with DNA-binding partners, including transcription factors, transcription co-activators 
and co-repressors. Runx2 is one of the transcription factors that physically interact with Smad1 
and Smad5 upon activation of BMP singaling, and co-operatively regulate the transcription of 
target genes, leading to osteoblast differentiation of mesenchymal osteoprogenitor cells (Lee et al 
2000; Zhang et al 2000). Among the many Runx2 target genes, osteocalcin (OCN), osteopontin 
(OPN), bone sialoproetin (BSP), and collagen I (COL1) are the known proteins that promote 
osteoblast differentiation of osteoprogenitor cells (Ducy and Karsenty 1995; Ducy et al 1997; 
Geoffroy Ducy and Karsenty 1995; Javed et al 2001; Kern et al 2001; Sato et al 1998). Smad3 
also interacts with Runx2 upon TGFβ stimulation, but unlike BR-Smads, the Smad3-Runx2 
complexes inhibit the transcription activity of Runx2 (Alliston et al 2001). It is recently found 
that Smad6 physically interacts with Runx2 and enhances the E3 ubiquitin liagase Smad ubiquitin 
regulatory factor 1 (Smurf1) mediated Runx2 degradation, which serves as a negative regulatory 
mechanism for BMP-Smad-Runx2 signaling pathway and inhibits osteoblast function and bone 
formation (Shen et al 2006). 
 Menin, the product of the MEN1 (multiple endocrine neoplasia I) gene, is another known 
transcription factor that interact with BR-Smads. It is required for commitment of multipotential 
mesenchymal stem cells through osteoblastic lineage at the early stage (Sowa et al 2003). Menin 
physically interact with both BR-Smads and Runx2 in mesenchymal stem cells and facilitates 
transcription activity of Runx2. In late stage of osteoblast differentiation, Menin interacts with 
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Smad3 and negatively regulates the BMP-Smad1/5-Runx2 signaling pathway leading to 
inhibition of osteoblast differentiation (Sowa et al 2004). 
 P300 and CBP (CREB binding protein) are transcriptional co-activators that induce 
transcription of target genes by increasing the accessibility to the general transcription machinery. 
P300 and CBP physically interact with various R-Smads upon ligand stimulation and enhance 
Smads-dependent transcription of target genes. P300 also binds to Runx proteins and stimulates 
Runx-dependent transcription. 
 Various BMP target genes have been identified, among which Id (inhibitor of 
differentiation) proteins are well documented and are one of the important target genes of BMPs 
(Ogata et al 1993). Id proteins are inhibitory helix-loop-helix (HLH) transcription factors, and 
function as negative regulator of differentiation and positive regulator of proliferation. The 
positive role of Id1 and Id3 in bone formation has been recently demonstrated (Maeda et al 2004; 
Peng et al 2004).  
 BMP signal can be regulated at multiple levels including 1) inhibition of BMP-BMP 
receptor interaction by extracellular BMP binding proteins; 2) presence of nonsignaling 
membrane pseudoreceptors; 3) blocking of BMP signaling by inhibitory  Smads and intracellular 
Smad binding proteins; and 4) ubiquitination and proteasomal degradation of BMP signaling 
effectors. The extracellular BMP antagonists represent a group of secreted peptides that bind 
BMPs with high affinity and prevent the interaction between BMPs and their specific receptors. 
At least four subgroups of BMP antagonists have been characterized. These include: Noggin; the 
chordin family; twisted gastrulation (Tsg); and the Dan family.  
 I.c. Regulation of osteoblast differentiatin by Runx2 
 Runx2, also known as core binding factor α1 (Cbfa1), is an important regulator of 
osteoblast differentiation. The function of Runx2 in osteoblast differentiatin was first described as 
the transcription factor that binds to OSE2, a cis-acting element that located in the promoter 
region of the mouse Ocn gene, and controls the osteoblast-specific transcription of osteocalcin 
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(Ducy et al 1997). It has also been shown that overexpression of Runx2 in non-osteogenic cells 
induces the cells to express osteoblast related genes. On the other hand, decreased expression of 
Runx2 down-regulates the osteoblastic gene expression (Ducy et al 1997). Several extracellular 
matrix proteins, including osteocalcin, bone sialoprotein (BSP), collagen I α 1 (COL1a1), 
osteopontin (OPN), osteoprotegrin (OPG), receptor activator of NF-kappa-B ligand (RANKL), 
and collagenase 3, were reported as the putative target genes of Runx2 (Ducy et al 1997). The 
essential role of Runx2 in osteoblast differentiation was highlighted in null-mutation mice that 
had cartilaginous skeleton with absence of osteoblasts (Ducy et al 1997; Komori et al 1997; Otto 
et al 1997). The heterozygous mice have defects in the intramembranous ossification, showing 
hypoplasia of the clavicle and delayed ossification of calvarial bones, which resembles the 
symptoms of human claidocranial dysplasia, caused by mutations of RUNX2. In addition to its 
critical roles in osteoblast differentiation, Runx2 also plays an important role in chondrogenesis. 
The Runx2-null mice showed delayed chondrocyte maturation. Transgenic expression of Runx2 
in chondrocytes results in ectopic chondrocyte hypertrophy and endochondral ossification, 
indicating that Runx2 controls differentiation of hypertropic chondrocytes and osteoblasts. It has 
been shown that Runx2 controls the expression of collagenase 3, collagen X, and vascular 
endothelial growth factor (VEGF) in hypertrophic chondrocytes. 
 The dual roles of Runx2 suggested the presence of additional factors that controls 
osteoblast differentiation. Nakashima et al. 2002 identified a novel zing finger-containing 
transcription factor called Osterix (Osx, also named transcription factor sp7) from mouse C2C12 
skeletal muscle progenitor cells in response to BMP-2. Osx is specifically expressed in all 
developing bones, but not in the epithelial tissue of tooth germs. In situ hybridization of human 
embryonic tissues revealed OSX expression in osteoblastic cells of the appendicular and 
craniofacial skeleton. Osx-null mice developed normally patterned skeleton composed entirely of 
cartilage, with absence of osteoblasts and mineralized bone matrix. Unlike Runx2 deficient mice, 
the cartilage in Osx-null mice was normal, containing fully mineralized, terminally differentiated 
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hypertrophic chondrocytes, suggesting the specific role of Osx in osteoblast differentiation. 
Interestingly, the Osx-null mutants expressed Runx2 at the levels comparable to wild-type mice, 
indicating that Osx was not required for Runx2 expression. However, Osx was not expressed in 
Runx2-null mice, which suggested that Runx2 is required for Osx expression and Osx acted 
downstream of Runx2.  
 A number of transcription factors or cofactors have been shown to interact with Runx2 
and regulates its transcription activity. AJ18, a zinc finger-containing factor, suppresses Runx2-
mediated transcription activity by competing for the DNA-binding sequence (Jheon et al 2001). 
Cui et al. 2003 has identified a transcription coactivator with PDZ-binding motif, named Taz, 
interacts with Runx2 and regulates osteoblast differentiation. Hong et al. 2005 further showed 
that Taz coactivates Runx2-dependent gene transcription while represses peroxisome proliferative 
activated receptor γ (PPARγ)-dependent gene transcription. It functions as a molecular switch 
that modulates mesenchymal stem cells differentiation by promoting osteoblast differentiation 
while simultaneously impairing adipocyte differentiation. 
 Distal-less homeobox 5 (Dlx5) and msh homeobox homologue 2 (Msx2) are homeobox-
containing transcription factors expressed in early stage of osteoblast differentiation. Dlx5 mutant 
mice present delayed skull ossification as well as severe craniofacial defects (Acampora et al 
1999). Similarly, Msx2-deficient mice also showing defects of skull ossification and 
endochondral bone formation (Satokata et al 2000). Recent study has demonstrated that Dlx5 
initiated the osteogenic differentiation of primary cells by triggering the expression of Runx2 and 
other osteoblast related genes, such as ALP and osteopontin (Holleville et al 2007). It has been 
shown in different studies that both Dlx5 and Msx2 bind to the homeodomain-response element 
in the Runx2 promoter and the promoters of other osteoblast markers, such as ALP, COL1a1, and 
BSP. Dlx5 functions as a transcription activator, whereas Msx2 acts as a repressor (Barnes et al 
2003; Benson et al 2000; Dodig et al 1996; Kim et al 2004; Lee et al 2005; Shirakabe et al 2001).  
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 II. Wnt signaling pathway and osteoblastic differentiation 
 II.a. Introduction 
 Wnt is named based on the relationship of this family to the Drosophila segment polarity 
gene 'wingless' and to its vertebrate ortholog, int-1, a mouse protooncogene that was first 
identified as targets for insertional activation by the mouse mammary tumor virus (MMTV) in 
mammary carcinomas. Wnt gene family encodes a group of revolutionary-conserved secreted 
cysteine-rich glycoproteins and known to include at least 22 members in vertebrate and 19 
members in human and mouse. The Wnt family of signaling molecules has been implicated in 
oncogenesis, embryonic development, and regeneration of adult tissues, such as lymphoid tissue, 
skin, hair follicles, and bone.   
 II.b. Wnt signaling pathways 
  Wnt signals are propagated by binding to the cysteine-rich extracellular domain (CRD) 
of Frizzled, a seven-transmembrane cell surface receptor. The low-density lipoprotein receptor 
related protein (LRP) family, such as LRP5 and LRP6, are also recognized as the coreceptors of 
the Wnt signaling (Tamai et al 2000). At least three different pathways have been demonstrated to 
be mediated by Wnt signaling. The canonical Wnt pathway is regulated by the presence or 
absence of intracellular β-catenin. A large multiprotein complex including proteins of APC and 
Axin families facilitates the phosphorylation of β-catenin by glycogen synthase kinase 3β 
(GSK3β). Phosphorylated β-catenin binds to a protein called βTrCP, and is then modified by the 
covalent addition of ubiquitin. Proteins tagged with ubiquitin are degraded by the proteosome. 
With the stimulation of Wnt ligands, Wnts bind to the frizzled cell surface receptors and activate 
the phosphoprotein dishevelled (dsh), which then inhibits the activity of GSK3β. Beta-catenin 
thus remains hypophosphorylated, accumulates in the cytoplasm, and then translocates to the 
nucleus, where it binds to a DNA binding protein of the T-cell factor/ lymphocyte enhancer factor 
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(TCF/Lef) transcription factors, and activates new gene expression together (Cadigan and Nusse 
1997; Gradl Kuhl and Wedlich 1999; Peifer and Polakis 2000; Sokol 1999).  
 The second pathway activated in response to Wnt ligands signals via the small GTPases 
Rho and Cdc42 to c-Jun N-terminal kinase (JNK) and directs asymmetric cytoskeletal 
organization and coordinated polarization of cell morphology. In vertebrates, this pathway 
regulates convergent extension movements (Boutros et al 1998; Yamanaka et al 2002). The third 
pathway mediated by some Wnts can stimulate the release of intracellular Ca2+, activating protein 
kinase C (PKC) and Ca2+/calmodulin-dependent kinase II (CamkII) (Kuhl et al 2000; Sheldahl et 
al 1999).  
 Wnt5a, together with Wnt4 and Wnt11, has been defined as a distinct class from the 
classical Wnts (Wnt1 class), because it appears not to mediate the canonical pathway, but to 
activate the JNK pathway and/or PKC/Ca2+ pathway. However, it has been demonstrated that 
Wnt5a can also activate the β-catenin-dependent pathway in morphological arrangement of 
cardiac myocytes (Toyofuku et al 2000). The diversity of the downstream signal transduction 
pathways appears to depend upon what receptors are presented by the cell (Church and Francis-
West 2002). FZD5, FZD7, FZD4, and FZD2 have been demonstrated to be the putative receptors 
of Wnt5a at different models (Chimal-Monroy et al 2002; He et al 1997; Kawakami et al 1999; 
Sen et al 2001; Toyofuku et al 2000; Umbhauer et al 2000). However, which receptor is utilized 
by osteoprogenitors or MSCs is not clear.  
 Fibronectin, OCN, MSX2, BMP4, and many other genes that are implicated in 
osteoblastic differentiation, have been shown to be the putative target genes of β-catenin pathway 
(Gradl Kuhl and Wedlich 1999; Kahler and Westendorf 2003; Willert et al 2003). It has also been 
suggested that BMP pathway and Indian hedgehog (Ihh) pathway are related to Wnt/β-catenin 
signaling pathway (Bain et al 2003; Church et al 2002; Fischer Boland and Tuan 2002a; Fischer 
Boland and Tuan 2002b; Yang et al 2003). It has been shown that activation of β-catenin pathway 
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induces ALP mRNA and protein (Bain et al 2003), which suggested its function in osteoblast 
differentiation. JNK pathway and PKC/Ca2+ pathway have been shown to be involved in 
osteoblastic differentiation. Both pathways have been reported to activate the transcriptional 
factor activating protein-1 (AP-1) complex, which plays a critical role in osteoblastic 
differentiation (Granet et al 2002; Papachristou et al 2003). Functional binding sites have been 
found in the promoter regions of several genes expressed in osteoblasts, including ALP, α1(1) 
collagen, and OCN (McCabe et al 1996). Besides, JNK has been found to be activated during in 
vitro osteoblastic differentiation of hMSCs after 7 to 13 days OS treatment (Jaiswal et al 2000). 
PKC pathway has been reported to be involved in regulating Runx2 expression and its 
transactivation (Kim et al 2003). Which signaling pathway(s) is/are utilized during osteoblastic 
differentiation of hMSCs is yet to be determined. 
 II.c. Wnt5a 
 Wnt5a plays an important role in the skeletal development, which is underscored by the 
limb deformities of the Wnt5a knockout mouse. Disruption of Wnt5a results in the shortening of 
the long bone, and deformity of craniofacial skeleton (Yamaguchi et al 1999). Potential function 
of Wnt5a on bone remodeling has also been indicated in rat bone fracture healing model, where 
Wnt5a has been detected as the only upregulated Wnt family gene. Together with Wnt5a, other 
Wnt signaling pathway components such as Frizzled, Casein Kinase II, β-catenin, and PP2A 
(protein phosphatase 2A) are also upregulated during fracture healing (Hadjiargyrou et al 2002).  
 The potential role of Wnt5a in osteoblastic differentiation has been suggested by recently 
published in situ hybridization results (Yang et al 2003). In wild type mouse, the expression 
pattern of Wnt5a was found to be overlapped with Runx2, which is a well-defined transcription 
factor that controls osteoblastic differentiation of MSCs (Ducy et al 1997).  Furthermore, 
disrupted or delayed osteoblastic differentiation in the Wnt5a knockout mice was indicated by the 
absence of osteocalcin, the well-known marker of mature osteoblasts (Yang et al 2003).   
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 Our preliminary data further confirmed the expression of Wnt5a and its receptor by 
hMSC during its differentiation along osteoblastic lineage. We have identified that Wnt5a 
expression level is increased at the early stage of osteoblastic differentiation, and then decreased 
later. Transcripts of one of the candidate receptors of Wnt5a, hFZD5, and the coreceptor of Wnt 
signaling pathway, hLRP5, were also detected during osteoblastic differentiation of hMSCs. All 
these previous work has suggested the function of Wnt5a on osteoblastic differentiation of 
hMSCs. However, whether Wnt5a signaling is necessary or sufficient for hMSCs differentiation 
into osteoblasts is not known as yet.  
 Although we have known that Wnt5a has the potential to activate all three Wnt pathways, 
including JNK pathway, PKC/Ca2+ pathway and β-catenin pathway (Slusarski et al 1997; 
Toyofuku et al 2000; Yamanaka et al 2002), the specific pathway utilized during osteoblastic 
differentiation is unclear. Uncovering the downstream signaling pathway and the regulated genes 
of Wnt5a will contribute to uncovering the mechanisms how Wnt5a regulates osteoblastic 
differentiation of hMSCs, and to understanding the interrelationship between different signaling 
pathways that control osteoblastic differentiation.  
 II.d. LRP5  
 The LRP5 gene, located on human chromososme 11q13, contains 23 exons encoding a 
deduced 1,615-amino acid protein containing conserved modules characteristic of the low density 
lipoprotein receptor (LDLR) family, including a putative signal peptide, 4 β-propeller domains 
(containing YWTD motifs separated by an epidermal growth factor (EGF)-like repeat), 3 LDLR 
repeats, a single transmembrane-spanning domain, and a cytoplasmic domain (Dong et al 1998). 
The deduced 1,613-amino acid human LRP6 protein is 71% identical to human LRP5. The LRP5 
and LRP6 proteins share similar structures; compared to known LDLR family members, they 
display a unique pattern of EGF and LDLR repeats in the extracellular domain and have proline-
rich motifs but no NPXY motif in the cytoplasmic domain. The homolog of LRP5 or LRP6 in 
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Drosophila is called Arrow, which is genetically required for Wingless signaling (Wehrli et al 
2000).  
 The involvement of LRP5 and/or LRP6 in Wnt signaling pathway is suggested by several 
studies. Mouse LRP mutations have similar phenotype to Wnt mutants (Pinson et al 2000). In 
Xenopus, overexpression of LRP can activate Wnt signaling (Tamai et al 2000). Taimai et al, 
2000 suggested that Wnts can bind directly to the extra-cellular domain of LRP and form a 
ternary complex with the Frizzled receptor (Tamai et al 2000), However, the interaction between 
Wingless and Arrow was not detected in Drosophola (Wu and Nusse 2002). The LRP5/LRP6 
lacking the intracellular domain and the transmembrane domain functions as dominant-negative 
mutant (Mao et al 2001; Tamai et al 2000). LRP5/6 lacking the extracellular domain is 
constitutively active. There are several PPPSP motifs at the cytoplasmic domain of LRP5/6, 
which are phosphorylated by protein kinases, known as GSK3 and CK1γ, upon Wnt treatment 
(Davidson et al 2005; Zeng et al 2005). The phosphorylated domain on LRP5/6 interacts with 
Axin, which associates directly with β-catenin, GSK-3β and APC and is implicated in down- 
regulating Wnt signaling (Mao et al 2001; Tamai et al 2004; Tolwinski et al 2003). 
 Substantial genetic data suggest that LRP5 is a key determinant of bone mineral density 
(BMD). Gong et al (2001) have pinpointed 12 mutations to LRP5 in patients with osteoporosis-
pseudoglioma syndrome (OPPG), an autosomal recessive disorder characterized by low bone 
mass resulting in skeletal fragility, and blindness due to impaired blood vessel regression (Gong 
et al 2001). Alternatively, an autosomal dominant LRP5 mutation, G>T transversion in exon 3 
resulting in a G>V change at residue 171, has been described in patients with high bone mass 
(HBM) syndrome (Boyden et al 2002; Little et al 2002). Patients with HBM develop 
complications associated with excessive bone formation, such as cranial nerve compression and 
severe headache. Other LRP5 missense mutations (G171R, A214T, A214V, A242T, T252I) have 
been described in patients with bone mass disorders, including endosteal hyperostosis, autosomal 
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dominant osteopetrosis type I and osteosclerosis (Van Hul et al 2002; Van Wesenbeeck et al 
2003). A key role of LRP5 in controlling bone mass has also been addressed in mouse models. 
Knockout of Lrp5 expression in mice results in decreased BMD (Kato et al 2002). Transgenic 
mice expressing a gain-of-function human LRP5 (G171V) have increased trabecular BMD caused 
by increased osteoblast function as compared to mice expressing wild type LRP5 (Babij et al 
2003). 
 The significance of LRP5 function in control of bone mass is underscored by the growing 
list of single nucleotide polymorphisms (SNPs) found for the LRP5 gene. Numerous SNPs are 
cataloged and both intron and exon encoded SNPs have been linked to phenotypic changes in 
BMD (Bollerslev et al 2005; Ferrari et al 2004; Ferrari Deutsch and Antonarakis 2005; Koay et al 
2004; Koller et al 2005; Mizuguchi et al 2004; Urano et al 2004). One SNP located at the exon 18, 
c.4037 C>T (p.A1330V), is reproducibly associated with decreased BMD (Ferrari et al 2004; 
Ferrari Deutsch and Antonarakis 2005; Koay et al 2004; Koller et al 2005; Mizuguchi et al 2004). 
 II.e. WNT antagonists 
 Wnt signaling is tightly regulated by a large number of antagonists, including the Wnt 
inhibitory factor-1 (WIF-1), secreted Frizzled-related protein, dickkopf (Dkk), and Cerberus and 
WISE/sclerostin families. Sfrps and Wif1 act as decoy receptors antagonizing both canonical and 
non-canonical Wnt signaling. On the other hand, Dkk proteins and Sclerostin/Sost family proteins 
bind to LRP5/6 and lead to specific inhibition of canonical Wnt signaling. 
 Wnt inhibitory factor 1 (WIF1) was first identified as an expressed sequence tag (EST) 
from the human retina. The deduced 379-amino acid WIF1 secreted protein contains an N-
terminal signal sequence, a 150-amino acid WIF domain, five EGF-like repeats, and a C-terminal 
hydrophilic domain of approximately 45 amino acids. WIF directly binds to Wnt proteins through 
the N-terminal WIF domain, and inhibits their activities (Hsieh et al 1999). 
 Secreted frizzled-related protein (sFRP) contains a cysteine-rich domain (CRD) of 
approximately 110 residues that share 30 ~ 40% sequence similarity with the putative ligand-
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binding domain of FZ proteins, but lacks the 7-transmembrane motif that anchors FZ proteins to 
the plasma membrane (Finch et al 1997). Although sFRPs are secreted, they are mainly found at 
the plasma membrane and/or in the extracellular matrix. It is thought that association of sFRPs 
with heparin sulfate proteoglycans stabilizes sFRP-Wnt complexes and/or determines antagonist 
localization (Finch et al 1997). Among five of the sFRPs, sFRP1, sFRP2, and sFPR3 (also known 
as FrzB) are known to bind Wnt proteins and inhibits Wnt signaling pathway. Secreted FRP1 is 
thought to play a dominant role in bone. Ablation of sFRP1 in mice exhibits increased trabecular 
bone formation, which is possibly resulted from elevation of the bone formation rate, a 
suppression of osteoblast and osteocyte apoptosis, and an enhancement of osteoblast lineage cell 
proliferation, differentiation, and mineralization. Absence of other problems in other non-skeletal 
organs suggested that other sFRPs may compensate for the function of sFRP1 in non-skeletal 
tissues (Bodine et al 2004). 
 The DKK proteins are secreted and rich in cysteines. There are four DKK members in 
human genome. DKK1 and DKK2 proteins, but not DKK3 and DKK4, are known as negative 
regulators of WNT signaling.  Coexpression of DKK1 or DKK2 and WNT ligands blocked 
WNT-induced increase in β-catenin level, but not the Dsh- or Frizzled- induced signaling, 
indicating that DKK1 antagonize WNT function upstream of WNT receptors (Fedi et al 1999; 
Krupnik et al 1999). DKK1 and DKK2 inhibits WNT signaling by interacting directly with 
LRP5/6 and transmembrane proteins, Kremen 1 and Kremen 2, to form a ternary complex, and 
triggering the clearance of WNT co-receptor LRP5/6 from the plasma membrane by endocytosis 
(Mao et al 2001; Mao et al 2002).  
 The Dkk1-null mice die at birth with morphologic defects including a lack of anterior 
head structures and duplications and fusions of limb digits (Mukhopadhyay et al 2001). Deletion 
of a single allele of Dkk1 gene (Dkk1+/-) in mice leads to an increase in bone formation 
parameters, including number of osteoblasts, mineral apposition, and bone formation rate, leading 
to a marked increase in bone mass, with no change in bone resorption (Morvan et al 2006). 
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Endogenous Dkk1 expression is detected primarily in osteoblasts and osteocytes in adult mice. 
Overexpression of Dkk1in both rat primary calvaria cells and MC3T3E1 cells results in inhibition 
of osteoblast differentiation and formation of bone nodules in vitro (Li et al 2006; Morvan et al 
2006; Tian et al 2003). Osteoblast overexpression of Dkk1 transgenic mice results leads to 
osteopenia resulted from reduction of osteoblast numbers (Li et al 2006). The involvement of 
DKK1 in inhibition of osteoblast differentiation and/or osteoblast function has also been 
demonstrated in the field of systemic disease. The elevated systemic DKK1 levels in bone 
marrow plasma and peripheral blood from patients with multiple myeloma correlated with the 
gene expression patterns of DKK1 and were associated with the presence of focal bone lesions 
(Tian et al 2003). 
 The mechanism of DKK1 in determination of osteoblast differentiation has been further 
studied using mesenchymal stem cells (MSCs) culture model. Gregory et al (2003) found that 
DKK1 was highly expressed at rapid dividing hMSCs, but expressed at a very low level during 
the stationary phase of growth. DKK1 is involved in the re-entry of MSCs into the cell cycles by 
inhibition of canonical Wnt signaling pathway, thus prevents terminal differentiation of 
proliferating MSCs. As MSCs culture increases in density, DKK1 level diminishes, and the 
inhibition of osteoblastic differentiation of MSCs is relieved, allowing terminal differentiation in 
the presence of osteoinductive signals. (Gregory et al 2003; Gregory et al 2005; Prockop Gregory 
and Spees 2003).  
 Interestingly, knock-out mice lacking Dkk2 develop osteopenia rather than HBM (Li et al 
2005b). The oeteopenic phenotype is due to the decrease in osteoblastic progenitor cell 
proliferation, decrease in the terminal differentiation of osteoblasts, and increase in the number of 
osteoclasts. In addition, overexpression of Dkk2 at a certain stage of osteoblast differentiation 
could stimulate terminal differentiation of osteoblasts. The effects of Dkk2 on osteoclasts may 
result from the increased production of osteoclast-type cytokines, such as M-CSF and RANKL, 
by the less mature osteoblasts. The effects of Dkk2 on terminal osteoblast differentiation may not 
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be entirely mediated by antagonizing canonical Wnt signaling. It is also shown that the 
expression of Dkk2 is highly regulated by canonical Wnts (Li et al 2005b).     
 Sclerostin, encoded by the SOST gene, is predicted to be a secreted glycoprotein with 
homology to the DAN/cerberus family of BMP antagonists. SOST was originally identified 
because its association with the high bone mass sclerosteosis phenotype (Brunkow et al 2001). 
Sclerostin has been shown to bind BMPs selectively with higher affinity to BMP6 and BMP7. 
Sclerostin negatively regulates the formation of bone by inhibiting the differentiation and/or 
function of osteoblasts induced by BMPs through direct neutralization of the BMPs. 
Overexpression of human sclerostin in transgenic mice resulted in a marked decrease in 
osteoblast activity and decreased bone formation (Kusu et al 2003; Winkler et al 2003). Sclerostin 
interacts directly with Noggin, another BMP inhibitor, and attenuates the BMP antagonist activity 
of each other (Winkler et al 2004). Recently, it is reported that sclerostin could antagonize Wnt 
signaling in Xenopus embryos and mammalian cells by binding to the extracellular domains of 
the Wnt coreceptors Lrp5  and Lrp6 and disrupting Wnt-induced frizzled -Lrp complex formation 
(Ellies et al 2006; Li et al 2005a; Semenov Tamai and He 2005; Winkler et al 2004). LRP5 
mutations linked to HBM diseases exhibit reduced binding affinity to sclerostin and are resistant 
to sclerostin mediated Wnt inhibition (Ellies et al 2006; Semenov and He 2006). The difference 
between Dkk1- and sclerostin- mediated LRP5/6 inhibition is the binding site. Sclerostin binding 
and inhibition is primarily mediated by the first and possibly the second β-propeller domains of 
LRP5/6, whereas DKK1 binding and inhibition is mainly via the third and possibly the fourth β-
propeller domains of LRP5/6. (Ellies et al 2006; Semenov and He 2006).     
 II.f. Wnt signaling pathway and the control of bone formation 
 Genetic studies of OPPG and HBM have suggested the key role of LRP5 in control of 
bone mass, which further indicated the involvement of Wnt signaling pathway in osteogenesis 
(Johnson 2004). Skeletal phenotypes have also been noted when other Wnt signaling components 
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have been altered in mice. Transgenic mice that overexpress Wnt10b in bone marrow 
mesenchymal progenitor cells have significantly increased bone mass, while Wnt10b null mice 
exhibit decreased bone mass (Bennett et al 2005). Tissue-specific deletion of β-catenin in skeletal 
precursor cells in developing mice leads to complete failure of osteoblast differentiation (Hu et al 
2005). Alterations in bone mass have also been observed in mice with osteoblast-specific 
deletions of β-catenin or Apc, with the former having low bone mass and the latter increased 
bone mass (Holmen et al 2005). Ablation of sFRP1, a known Wnt antagonist, in mice exhibits 
increased trabecular bone formation (Bodine et al 2004). In addition, osteoblast-specific 
overexpression of Dkk-1 in mice leads to reduced bone mass (Li et al 2006). It is concluded to 
date that canonical Wnt signaling pathway plays an important role in osteogenesis. However, the 
implication of non-canonical Wnts is not well known.   
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CHAPTER II 
 
 
Influence of an LRP5 cytoplasmic SNP on Wnt signaling and 
osteoblastic differentiation 
Abstract 
 
The low density lipoprotein receptor-related protein 5 (LRP5) is a key determinant of bone 
mass, via the Wnt signaling pathway control of osteoblast function. This study examined human 
LRP5 signaling and the effects of an intracellular domain single nucleotide polymorphism (SNP: 
p.V1525A) on osteoblast differentiation and mineralization. Constitutively active LRP5 was 
constructed by deletion of the extracellular domain of LRP5 (LRP5ΔN). Expression of LRP5ΔN-
V, which carries the allele p.1525V, induced higher β-catenin/TCF-LEF activity compared to 
LRP5ΔN-A, which carries the allele p.1525A. In a yeast two-hybrid assay, LRP5ΔN-V also 
demonstrated a stronger interaction with AXIN than LRP5ΔN-A. Expression of either of the 
alleles did not change cell proliferation. However, cells expressing LRP5ΔN-V showed increased 
alkaline phosphatase activity and bone nodule formation compared to cells transfected with 
empty vector or LRP5ΔN-A after osteogenic supplement (OS: β-glycerophosphate and L-
ascorbic acid) treatment. Cells expressing LRP5ΔN-V revealed significantly increased bone 
sialoprotein (BSP) expression after 7 days of OS treatment and maintained elevated expression 
until day 21. Osteocalcin (OCN) mRNA levels were increased after 14 - 21 days of OS treatment 
in LRP5ΔN-V expressing cells. LRP5ΔN-V expressing cells demonstrated positive interaction 
with BMP-2 signaling of transcription at the SBE-luc promoter. LRP5 signaling is affected by the 
cytoplasmic SNP, p.V1525A. mRNA levels of Runx2 and Osterix were not affected by this SNP.   
 
Introduction 
 
The WNT gene family consists of structurally related genes encoding secreted cysteine-rich 
glycoproteins that have been implicated in oncogenesis, embryonic development, and 
regeneration of adult tissues, such as lymphoid tissue, skin, hair follicles, and bone. Wnt ligands 
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function by signaling through transmembrane co-receptors encoded by the low density 
lipoprotein receptor-related protein (LRP5/6) and Frizzled (FZD) gene families. Binding of 
specific Wnts to the Frizzled receptors results in activation of Dishevelled (Dsh) and other 
proteins, which facilitates dissociation of the β-catenin-adenomatous polyposis coli protein 
(APC)/AXIN/glycogen synthase kinase 3β (GSK3β) complex and prevents β-catenin from being 
phosphorylated. β-catenin subsequently translocates into the nucleus and activates the T cell 
factor (TCF)/lymphoid-enhancing factor (LEF) 1 transcription factor (Nusse 2005; Reya and 
Clevers 2005).  
The LRP5 gene, located on human chromososme 11q13, contains 23 exons encoding a 1615 
amino acid single pass transmembrane receptor that belongs to the low density lipoprotein (LDL) 
receptor superfamily (Dong et al 1998; Hey et al 1998). LRP5 contains a large extracellular 
domain bearing YWTD spacer repeats, 4 epidermal growth factor-like (EGF) repeats, and 3 LDL 
receptor-like (LDLR) ligand binding domains. The short cytoplasmic tail possesses five serine 
phosphorylation sites (PPPSP motifs) that are essential for downstream signaling (Brennan et al 
2004; Tamai et al 2004). Activation of Wnt signaling leads to phosphorylation of the cytoplasmic 
tail by yet to be identified cellular kinases, thereby enabling interaction with Axin (Mao et al 
2001; Tamai et al 2004). This interaction results in inhibition of GSK3β-dependent 
phosphorylation of β-catenin, leading to stabilization of β-catenin and activation of TCF/LEF1-
mediated transcription. The significance of the LRP5 cytoplasmic domain in mediating 
downstream signaling has been evidenced by different mutation strategies. Deletion of the 
cytoplasmic domain causes dominant inactivation of Wnt signaling (Tamai et al 2000). 
Expression of the cytoplasmic domain has also been shown to constitutively increase free β-
catenin levels and activate TCF/LEF mediated transcription in a Wnt and FZD-independent 
fashion (Liu et al 2003; Tamai et al 2004).  
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 Substantial genetic data suggest that LRP5 is a key determinant of bone mineral density 
(BMD). Gong et al (2001) have pinpointed 12 mutations to LRP5 in patients with osteoprosis-
pseudoglioma syndrome (OPPG), an autosomal recessive disorder characterized by low bone 
mass and blindness (Gong et al 2001). Alternatively, an autosomal dominant LRP5 mutation, 
G>T transversion in exon 3 resulting in a G>V change at residue 171, has been described in 
patients with high bone mass (HBM) syndrome (Boyden et al 2002; Little et al 2002). Other 
LRP5 missense mutations (G171R, A214T, A214V, A242T, T252I) have been described in 
patients with bone mass disorders, including endosteal hyperostosis, osteopetrosis type I and 
osteosclerosis (Van Wesenbeeck et al 2003). A key role of LRP5 in controlling bone mass has 
also been addressed in mouse models. Knockout of Lrp5 expression in mice results in decreased 
BMD (Kato et al 2002). Transgenic mice expressing a gain-of-function human LRP5 (G171V) 
have increased trabecular BMD caused by increased osteoblast function as compared to mice 
expressing wild type LRP5 (Babij et al 2003).     
The significance of LRP5 function in control of bone mass is underscored by the growing list 
of single nucleotide polymorphisms (SNPs) found for the LRP5 gene. Numerous SNPs are 
cataloged and both intron and exon encoded SNPs have been linked to phenotypic changes in 
BMD (Bollerslev et al 2005; Ferrari et al 2004; Ferrari Deutsch and Antonarakis 2005; Koay et al 
2004; Koller et al 2005; Mizuguchi et al 2004; Urano et al 2004). One SNP located at the exon 18, 
c.4037 C>T (p.A1330V), is reproducibly associated with decreased BMD (Ferrari et al 2004; 
Ferrari Deutsch and Antonarakis 2005; Koay et al 2004; Koller et al 2005; Mizuguchi et al 2004). 
The majority of the other SNPs observed are synonymous mutations occurring in the extracellular 
domain. Interestingly, there exist non-synonymous polymorphisms in the cytoplasmic domain 
that are presently uncharacterized. The SNP c.4574T>C (refSNP ID: rs11574422) is located at 
the exon 22 of LRP5, resulting protein residue change of V1525A (Koay et al 2004; Toomes et al 
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2004). The aim of this study was to define the effect of this cytoplasmic SNP on the 
osteoprogenitor cell phenotype displayed in established cell culture models. 
 
Materials and Methods 
 
Construction of expression plasmids and mutagenesis 
 
The LRP5 cDNA fragment encoding the transmembrane and cytoplasmic domains of human 
LRP5 (LRP5ΔN) was amplified by high fidelity Pfu Turbo DNA polymerase (Stratagene, La 
Jolla, CA) using a vector containing the coding region of the full-length human LRP5 as the 
template (gift from Dr. He, GeneBank Accession No: NM_002335). The amplified LRP5 
fragment was then inserted into the pCMV-tag5a (Stratagene) vector between the EcoRI and XhoI 
sites with a myc tag at the C-terminus. Mutation representing the SNP c.4574T>C (p.V1525A) 
was performed by PCR based site-directed mutagenesis in E.coli strain XL-10 Gold (Stratagene) 
(Fig. 1A). Automated sequence analysis (ABI 3730 and 3100 DNA Analyzers) confirmed the 
fidelity of the inserted cDNA and the indicated mutation. 
 
Cell culture  
 
MC3T3-E1 (clone #4) cells were maintained in α-MEM with 10% FBS and 100 units/ml 
penicillin/streptomycin. C3H10T1/2 cells were cultured in DMEM with 10% FBS and 100 
units/ml penicillin/streptomycin. Growth medium was changed every three days. To induce 
osteoblastic differentiation of the MC3T3-E1 cells, cell culture medium was supplemented with 
2.5 mM β-glycerophosphate (Sigma, St. Louis, MO) and 50 μg/ml of L-ascorbic acid (Sigma) 
(Franceschi and Iyer 1992). Cell differentiation medium was replaced every other day.  
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Stable and transient transfection 
 
A non-liposomal based lipid transfection method (Effectene transfection reagent, Qiagen Inc, 
Valencia, CA) was used to achieve both stable and transient tranfections. Stable transfection was 
performed using 1 μg of linearized plasmid. 2.0 x 104 cells were seeded in 60 mm tissue cultural 
dishes the day before transfection. Fourty-eight hours after transfection, neomycin-resistant cells 
(600 μg/ml of neomycin, Invitrogen, Carlsbad, CA) were selected, and pooled for further analysis. 
Transient transfections were performed in 12-well tissue cultural plates for luciferase assays and 
100 mm tissue culture dishes for Western blot analysis.  
 
Preparation of whole cell lysate (WCL) and cellular fractions 
 
Whole cell lysates were prepared using ice-chilled Radio-Immunoprecipitation Assay (RIPA) 
lysis buffer containing Tris-HCl: 50 mM, pH 7.4, NP-40: 1%, Na-deoxycholate: 0.25%, NaCl: 
150 mM and 1 x Halt protease inhibitor cocktail (Pierce, Rockford, IL). Cytoplasmic and nuclear 
fractions were prepared using the NE-PER nuclear and cytoplasmic extraction reagents (Pierce) 
according to the manufacture’s protocol. The protein concentrations standardized against BSA 
were determined using the BCA protein assay (Pierce).    
 
SDS-PAGE and Western blot analysis  
 
Protein lysates were denatured at 100oC for 5 min in NuPAGE sample buffer containing DTT 
(Invitrogen) and separated using a 10% SDS-PAGE gel. For Western blots, proteins were 
transferred onto the PVDF membrane using Semi-dry Transfer system (Bio-Rad, Hercules, CA). 
The membranes were then blocked in 1 x TBST with 5% dry milk for 2 hr at room temperature, 
and hybridized with primary antibodies overnight at 4oC and the Horseradish Peroxidase (HRP)-
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conjugated sheep anti-mouse antibody (Amersham, Piscataway, NJ) 1 hr at room temperature. 
Immunoconjugates were detected using the SuperSignal chemoluminescent Substrate reagents 
(Pierce). The primary antibodies were from the following sources: anti-c-myc antibody from 
Roche (Indianapolis, IN), anti-actin from Chemicon international (Temecula, CA), anti-histone 
H1 from Stressgen biotechnologies (San Diego, CA), and anti-β-catenin from BD biotechnology 
(Franklin Lakes, NJ). 
 
Alkaline phosphatase (ALP) staining 
 
Cell layers in 35 mm cell culture dishes were fixed in ice cold citrate:acetone:formaldehyde 
(25:65:8) fixation solution for 1 min. After rinsing with 1x PBS, cell layers were then stained 
with an Alkaline Phosphatase kit (Sigma) at 37oC for 30 min, and washed with 1x PBS for 5 
times.  
 
Alizarin red staining 
 
Cell layers were fixed with 100% methanol for 10 min at room temperature. After rinsing 
with 1x PBS, cells layers were then stained with 1% Alizarin red (pH=4.2, Sigma) for 2 min, and 
rinsed with tap water. 
 
Colony Formation Unit (CFU) assay 
 
500 cells were seeded onto 35mm culture dishes. After culturing for 7 days, cell layers were 
washed with 1x PBS and then fixed in 100 % methanol for 10 minutes at room temperature. The 
cultured colonies were stained with 2.5% crystal violet in 70% methanol for 5 min at room 
temperature, rinsed in water and the colonies were counted. 
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 Proliferation assay 
 
2.0 x 104 cells / well were seeded onto 6-well plates, and dissociated with 0.05% Trypsin-
EDTA on days 0 to 5. Cell suspensions were stained with 0.4% Trypan blue (Invitrogen) for 5 
min at room temperature. The cell numbers, excluding Trypan blue-positive cells, were 
determined by manual counting (triplicate wells) in a hematocytometer.   
 
Quantitative Real-time PCR 
 
Total RNA isolated from MC3T3-E1 cells (transfected with LRP5ΔN-A, LRP5ΔN-V, or 
empty vector) was reverse transcribed. FAM dye-labeled mouse bone sialoprotein (BSP, ABI 
assay No. Mm00492555_ml), osteocalcin (OCN, Forward: 5’- GAG GGC AAT AAG GTA GTG 
AAC AGA -3’; Reverse: 5’- CAA GCA GGG TTA AGC TCA CAC T -3’), Runx2 (ABI assay 
No. Mm00501578_ml), and Osterix (ABI assay No. Mm00504574_ml), and VIC dye-labeled 
rodent G3PDH (ABI assay No. 4308313) were amplified using TaqMan Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA). Results were analyzed using the Applied Biosystems 
7500 Real-Time PCR System software. Messenger RNA levels of BSP, OCN, Runx2, and 
Osterix relative to G3PDH were determined and the fold changes were calculated using the 
values of undifferentiated samples (day 0) as the calibrators by means of 2-ΔΔCt method (Livak and 
Schmittgen 2001).  
 
Immunofluorescence assay (IFA) 
 
Cell layers on 8-well chamber slides were fixed by 2% paraformaldehyde in PBS for 20 min 
at room temperature, and then permeabilized using 0.3% triton-X100 (Sigma) for 30 min on ice. 
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Cell layers were then blocked with 20% normal goat serum, followed by monoclonal mouse 
primary antibody (1:50) and Alexa Fluor 488-conjugated goat anti-mouse secondary antibody 
(1:200; Invitrogen) treatment. The signal was then analyzed by laser-scanning confocal 
microscopy (Olympus FV500) using the FITC filter. Nuclear DNA was visualized using ToPro-3 
(Invitrogen).  
 
TopFlash Luciferase reporter assay and β-galactosidase (β-gal) assay  
 
C3H10T1/2 Cells were seeded onto 12-well plates one day before transfection. TopFlash 
vector (Upstate, Chicago, IL), was co-transfected with increasing amounts (0 – 0.4 μg) of 
LRP5ΔN fragments (LRP5ΔN-A or LRP5ΔN-V) and β-gal reporter. pcDNA3-LacZ was used to 
balance the amount of DNA. Forty-eight hours after transfection, cells were harvested in passive 
lysis buffer and subjected to catalytic reaction using beetle luciferin as the substrate and ATP-
Mg2+ as a co-substrate (Promega, Madison, WI). Luciferase activity was measured using a plate 
reading luminometer (Victor3, Perkin Elmer). The cell lysates were also subjected to β-gal assay 
by incubating with 1x β-gal reagent (100 mM Na2HPO4, 1 mM MgCl2, 100 mM β-
mercaptoethanol, and 0.67 mg/ml o-nitrophenyl galactopyranoside) at 37oC for 30 min. 
Absorbance at 405 nm wave length was recorded and used to normalize the measured luciferase 
activity. 
 
SBE-luc Luciferase reporter assay 
 
C3H10T1/2 cells were seeded onto 12-well plates one day before transfection. SBE-luc (a 
Smad3/4-specific reporter construct) was co-transfected with increasing amounts (0 – 0.4 μg) of 
LRP5ΔN fragments (LRP5ΔN-A or LRP5ΔN-V) and β-gal reporter. The total amount of DNA 
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was balanced with pcDNA3-lacZ. Six hours after transfection, increasing amounts (0 - 50 ng/ml) 
of human recombinant BMP2 (R&D Systems, Minneapolis, MN) was added into the medium. 
Cells were lysed 24 hours after transfection and subjected for luciferase activity measurement and 
β-gal assay as described above.   
 
Yeast two-hybrid assay  
 
LRP5∆N cDNAs carrying either the c.4574T or c.4574C nucleotide were inserted into 
pGBKT7 vector (Clontech, Mountain View, CA), creating a fusion protein with the DNA binding 
domain. Constructs expressing the activation domain fused to the full length human AXIN cDNA 
(original construct from Dr. Raab-Traub, University of North Carolina) was cloned into the 
pGADT7 plasmid (Clontech). The pGBKT7-LRP5∆N and the pGADT7-AXIN plasmids were 
cotransformed into the AH109 yeast strain (Clontech). Colonies expressing both LRP5∆N-BD 
and AXIN-AD were selected with SD/-Trp/-Leu plates. The positive clones were then re-streaked 
onto the SD/-Trp/-Leu/-His plates to select minor interaction clones and the SD/-Trp/-Leu/-His/-
Ade plates for selection of strong interaction clones.   
 
Results 
 
The LRP5 c-terminus SNP, p.V1525A, modulates β-catenin signaling 
 
The ability of LRP5ΔN to activate β-catenin signaling independent of Wnt ligands has been 
previously demonstrated (Mao et al 2001; Tamai et al 2004). To determine any potential 
functional difference of the c-terminus non-synonymous SNP, p.V1525A, in mediating 
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downstream signaling, c-myc-tagged LRP5ΔN-A and LRP5ΔN-V constructs were generated. 
Downstream signaling components were evaluated by means of a transient transfection strategy.  
Activation of canonical Wnt signaling pathway results in β-catenin stabilization and nuclear 
translocation, which consequently activates the TCF/LEF mediated transcription (Nusse 2005; 
Reya and Clevers 2005). In this study, C3H10T1/2 cells were transiently transfected with 
LRP5ΔN plasmids carrying the SNP 1525A or 1525V. Empty vector transfected cells served as 
controls. Immunofluorescence microscopy was used to characterize β-catenin expression and 
localization in the LRP5ΔN-V versus LRP5ΔN-A expressing cultures (Fig. 1B-E). All cultures 
including the empty vector transfected cells demonstrated β-catenin staining in the cytoplasm. β-
catenin was also identified in the nucleus of both the LRP5ΔN-V and LRP5ΔN-A expressing 
cells. However, LRP5ΔN-V expressing cells showed more nuclear staining than the LRP5ΔN-A 
transfected cells (Fig. 1B-D). Western blot analysis of the cytoplasmic and nuclear fractions from 
transiently transfected C3H10T1/2 cells was used to further demonstrate the translocalization of 
β-catenin to the nucleus. Transient transfection efficiency was controlled by myc expression in 
the whole cell lysates. The β-actin and Histone H1 levels served as controls for evaluation of 
cytoplasmic and nuclear β-catenin levels (Fig. 1F). Consistent with the previous 
immunofluorescence experiment, cells expressing LRP5ΔN-V showed a 70% higher 
nuclei/cytosol β-catenin ratio than cells expressing LRP5ΔN-A. The empty vector transfected 
cells showed the least amount nuclear β-catenin translocation (Fig. 1G).      
To further understand whether the LRP5, p.V1525A, eventually affected TCF/LEF mediated 
transcription via these observed changes in β-catenin, TCF/LEF activity was examined using 
TopFlash (TCF/LEF binding site) and FopFlash (mutant TCF/LEF binding sites) constructs. 
Transfection of C3H10T1/2 cells with increasing amount of either LRP5ΔN-V or LRP5ΔN-A 
results in increased TopFlash luciferase activity, with higher activity in LRP5ΔN-V versus 
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LRP5ΔN-A expressing cells (Fig. 2). As the negative control, FopFlash activity was minimal and 
showed no difference in either LRP5ΔN-A or LRP5ΔN-V transfected cells (data not shown).     
It is well known that LRP5 mediates downstream signaling through its interaction with AXIN. 
Three PPPSP motifs located at the c-terminus of LRP5 molecule are phosphorylation-dependent 
sequences essential for AXIN binding and downstream signaling (Tamai et al 2004). The SNP, 
p.V1525A, is located between the first and the second PPPSP motifs. To better understand how 
this SNP affects its interaction with AXIN, the yeast two-hybrid strategy was used to evaluate the 
interactions of AXIN and the LRP5ΔN-A or LRP5ΔN-V constructs. The yeast strain AH109 
cotransformed with pGADT7-AXIN and pGBKT7-LRP5ΔN-A (or pGBKT7-LRP5ΔN-V) were 
selected and then re-streaked onto the SD/-Trp/-Leu/-His plates and SD/-Trp/-Leu/-His/-Ade 
plates for selection of weak and strong interaction respectively. The clones cotransformed with 
pGADT7-AXIN and pGBKT7-LRP5ΔN-A grew well on the SD/-Trp/-Leu/-His plates, but not on 
the SD/-Trp/-Leu/-His/-Ade plates, suggesting a weak interaction between AXIN and LRP5ΔN-A. 
However, strong interaction between AXIN and LRP5ΔN-V was indicated by robust growth of 
the cotransformed clones on the SD/-Trp/-Leu/-His/-Ade plates (Fig. 3).  
 
The LRP5 c-terminus SNP, p.V1525A, does not affect cell proliferation  
 
To evaluate the effects of the LRP5 c-terminus SNP, p.V1525A, on osteoblastic cell 
proliferation, MC3T3-E1 cells expressing LRP5ΔN-A-myc and LRP5ΔN-V-myc were generated 
by stable transfection. Cells transfected with empty vector served as the control. Expression of 
LRP5ΔN-A and LRP5ΔN-V constructs in MC3T3-E1 cells was confirmed by 
immunofluorescence assay and Western blot analysis. Pooled clones were used in this study. 
Similar level of c-myc- labeled protein expression determined by Western blot analysis confirmed 
the relative transfection efficiency among the two cell populations (Fig. 4A). 
Immunofluorescence assays also showed similar peri-membrane anti-myc-specific fluorescence 
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(Fig. 4B-G). Cell proliferation capability was first determined by manually counting the vital cell 
numbers after 0 - 5 days of cell growth. No significant difference was observed between cells 
expressing LRP5ΔN-A, LRP5ΔN-V, or the control cell cultures (Fig. 4H). The colony formation 
assay also showed no significant difference among three groups (Fig. 4I).       
 
The LRP5 c-terminus SNP, p.V1525A, alters osteoblastic differentiation  
 
To study the effects of LRP5 SNP, p.V1525A, on osteoblast differentiation, stably transfected 
MC3T3-E1 cells were differentiated in medium supplemented with 2.5 mM β-glycerophosphate 
and 50 μg/μl of L-ascorbic acid for 0 to 21 days. ALP activity and bone nodule formation 
capability were determined. Other osteoblastic markers, such as BSP and OCN, were also 
evaluated. 
ALP activity was detected 3 days after induction (data not shown) for the LRP5ΔN-V 
expressing cultures, and the signal was dramatically enhanced 7 to 14 days after induction (Fig. 
5A). However, the cells expressing LRP5ΔN-A and the control cultures showed much lower ALP 
activity compared to the cells expressing LRP5ΔN-V, with the lowest level in the LRP5ΔN-A- 
expressing cultures (Fig. 5A).  
Mineralization or bone nodule formation was examined by Alizarin red staining after 14 to 21 
days of culture in differentiation medium. The LRP5ΔN-V expressing cultures showed earlier and 
more bone nodule formation than the LRP5ΔN-A- and the control cultures (Fig. 5B).  
This LRP5 SNP, p.V1525A, may alter the gene expression profile associated with 
osteoblastic differentiation. Comparison of steady state mRNA levels in the stable transfected 
MC3T3-E1 cells revealed a unique profile for the LRP5ΔN-V versus LRP5ΔN-A expressing 
cultures. In the LRP5ΔN-V expressing cultures, BSP expression was elevated and remained 
elevated through the intermediate culture period (days 7 – 21; Fig. 6A). However, in both the 
LRP5ΔN-A and the control cultures, BSP expression was elevated after 3 – 7 days of osteogenic 
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supplements (OS) treatment, but decreased dramatically after 21 days. Comparison of the peak 
BSP mRNA levels (7 days after treatment) revealed 14 fold induction in LRP5ΔN-V expressing 
cultures compared to 11 fold and 9 fold induction for control and LRP5ΔN-A expressing cultures 
respectively (Fig. 6A). OCN mRNA levels were also compared after 0 – 21 days of OS treatment 
(Fig. 6B). The LRP5ΔN-V expressing cultures showed significantly higher levels of OCN 
expression compared to the LRP5ΔN-A and the control cultures after 14 - 21 days of treatment. 
No significant difference was found during 0 – 7 days of treatment (Fig 6B).  
To begin to understand how changes in osteoblastic gene expression could be altered by 
LRP5 signaling, the steady state levels of Runx2 and Osterix mRNA were also compared.  No 
significant differences in Runx2 or Osterix mRNA levels were detected during the 0 – 21 day 
culture period (Fig. 7A-B).  
 
The LRP5 c-terminus SNP, p.V1525A, affects BMP2 mediated signaling  
 
To further define whether the effects of LRP5 could be mediated by interaction with the BMP 
pathway, the effects of LRP5 expression on BMP-signaling at a BMP-specific (SMAD3/4) 
reporter gene expression were examined in a transient transfection assay. Transcriptional activity 
at the SMAD3/4-specific luciferase reporter construct, SBE-luc, was increased in a BMP2-
dependent manner. However, cells transfected with LRP5ΔN-V showed even greater induction 
with or without BMP2 treatment compared to cells transfected with LRP5ΔN-A or empty vector 
(Fig. 8). 
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Figure 1. LRP5 SNP, p.V1525A, modulation of β-catenin signaling. A) Schematic 
representation of full length LRP5, LRP5ΔN-A and LRP5ΔN-V constructs. B-E) 
Immunofluorescence assay performed using anti β-catenin antibody and Alexa Fluor 488-
conjugated secondary antibody shows relative nuclear and cytoplasmic distribution of β-catenin 
(green) in LRP5ΔN-V transfected cells (B) and LRP5ΔN-V transfected cells (C). Corresponding 
nuclear stain by ToPro-3 (pink) of the images B and C are presented in images D and E, 
respectively. Images are representative of 5 individual fields examined. F) LRP5ΔN-V induces 
nuclear translocation of β-catenin in transient transfection. C3H10T1/2 cells in 100 mm dishes 
were transiently transfected with 2 µg of LRP5ΔN-A, LRP5ΔN-V, and pcDNA3 plasmids. Forty 
eight hours after transfection, cells were lysed, nuclear and cytoplasmic fractions were prepared. 
25 μg of cytoplasmic, nuclear, or the whole cell protein lysates (WCL) were used for SDS-PAGE 
and Western blot analysis. Lysates from cytosol, nuclei, and WCL were immunoblotted using 
primary antibodies specific to β-catenin, β-actin, histone H1, and c-myc (as shown). G) 
Densitometric analysis of β-catenin expression. The band density in the above Western blot was 
measured using Scion Image. Average normalized ratios of the nuclei β-catenin expression 
(normalized by histone H1 expression) over cytosol β-catenin expression (normalized by β-actin 
expression) was plotted.  
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Figure 2. Effect of LRP5 SNP, p.V1525A, on TCF/LEF transcription activity. C3H10T1/2 
cells in 12-well culture plates were transiently transfected with increasing amount (0 – 0.4 µg) of 
LRP5ΔN constructs, TopFlash (0.2 µg; TCF reporter plasmid) and β-gal reporter (0.05 µg) 
plasmids. LacZ plasmid was added to make the total amount of DNA equal. Forty eight hours 
after transfection, cells were lysed and subjected to luciferase and β-gal activity measurements. 
The measured luciferase activity was normalized by the corresponding β-gal activity. Studentized 
T test revealed differences between pcDNA3-LacZ transfected cells and LRP5ΔN-A or LRP5ΔN-
V transfected cells (* p<0.05). Significant differences were also defined between LRP5ΔN-A and 
LRP5ΔN-V transfected cells (** p<0.05). The result represents three independent experiments. 
Each experiment was carried out in triplicate.   
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Figure 3. Effect of LRP5 SNP, p.V1525A, on AXIN binding. The pGBKT7-LRP5∆N and the 
pGADT7-AXIN plasmids were cotransformed into the AH109 yeast strain. Colonies expressing 
both LRP5∆N-BD and AXIN-AD were selected with SD/-Trp/-Leu plates (not shown). The 
positive clones were then re-streaked onto the SD/-Trp/-Leu/-His plates to select weak interaction 
clones (left; A: pGBKT7-LRP5∆N-A, V: pGBKT7-LRP5∆N-V, and E: pGBKT7) and the SD/-
Trp/-Leu/-His/-Ade plates for selection of strong interaction clones (right). The images are 
representatives of five individual plates. 
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Figure 4. Effect of LRP5 SNP, p.V1525A, on cell proliferation. Expression of myc-tagged 
LRP5ΔN proteins was identified by Western blot and immunofluroscence assay. A) Western blot 
analysis of the whole cell lysates was used to confirm the relatively similar strength of LRP5ΔN-
A-myc and LRP5ΔN-V-myc expression (c-myc, as indicated), which is normalized by β-actin 
(lower panel). B-D) MC3T3-E1 cells were stable transfected using 2 μg of linearized plasmids. 
Immunofluorescence assay reveals vector-encoded expression of myc-tagged LRP5ΔN proteins 
(green) near the cell membrane in stable transfected MC3T3-E1 cells (LRP5ΔN-A and LRP5ΔN-
V) but not pcDNA3 transfected cells. These are the representatives of 5 similar images. E-G) 
Corresponding nuclear stain by ToPro-3 (blue) of the images B, C, and D. H) Cell proliferation 
was determined by colony formation units (CFU) assay. 500 cells were seeded onto the 35mm 
culture dishes one week before the assay. After culturing for 7 days, the colonies were stained 
with 2.5% crystal violet and counted manually. This experiment was carried out in triplicate. The 
error bars represent standard deviations. I) Cell proliferation was determined by counting cell 
numbers. 2.0 x 104 cells were seeded onto the 6-well plates, and harvested 5 days after seeding. 
Cell numbers with exclusion of Trypan blue- positive cells were determined by manual counting 
in a hematocytometer. This experiment was carried out in triplicate. The error bars represent 
standard deviations.  
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Figure 5. Effects of LRP5 SNP, p.V1525A, on osteoblastic differentiation. ALP activity and 
bone nodule formation were determined by ALP staining and Alizarin red staining respectively. 
A) LRP5ΔN-V transfected cells showed higher ALP activity after 7-14 days of OS treatment. B) 
LRP5ΔN-V expressing cells showed earlier and more bone nodule formation compared to 
LRP5ΔN-A and pcDNA3 transfected cells. These results are representatives of three independent 
experiments. 
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Figure 6. Effects of LRP5 SNP, p.V1525A, on osteoblastic gene expression. BSP and OCN 
expression levels were assayed by real-time PCR. A) After OS treatment, BSP expression in the 
LRP5ΔN-V transfected cells was elevated and remained elevated through the culture period (7 - 
21 days). However, the BSP expression in both LRP5ΔN-A and pcDNA3 transfected cells was 
decreased after 14 - 21 days of OS treatment. B) LRP5ΔN-V transfected cells also showed higher 
OCN mRNA induction compared to the LRP5ΔN-A and pcDNA3 transfected cells after 14-21 
days of OS treatment. These results are representatives of three independent experiments. 
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Figure 7. Effects of LRP5 SNP, p.V1525A, on osteoinductive gene expression. mRNA levels 
of RUNX2 and Osterix were assayed by real-time PCR. After OS treatment, both Runx2 (A) and 
Osterix (B) mRNA levels were increased. However, no significant differences were observed 
among the LRP5ΔN-A, LRP5ΔN-V, and pcDNA3 transfected cells. These results are 
representatives of three independent experiments.  
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Figure 8. Effects of LRP5 SNP, p.V1525A, on BMP2 signaling. C3H10T1/2 cells in 12-well 
culture plates were transiently transfected with increasing amount (0 – 0.4 µg) of LRP5ΔN 
constructs, SBE-luc (0.2 µg) and β-gal reporter (0.05 µg) plasmids. LacZ plasmid was added to 
make the total amount of DNA equal. Six hours after transfection, increasing amount of human 
recombinant BMP2 (0 – 50 ng/ml) was added into the medium. 24 hours after transfection, cells 
were lysed and subjected to luciferase and β-gal activity measurements. The measured luciferase 
activity was normalized by the corresponding β-gal activity. Two-way ANOVA defined 
significant effects of the LRP5ΔN constructs, BMP2 treatment, and the interaction between these 
two factors (p<0.001). Within group differences assessed by Tukey's Studentized Range (HSD) 
test revealed that 20 and 50 ng/ml of BMP2 treatment significantly increased the luciferase 
activity (p<0.05). Significant differences between LRP5ΔN-V transfected cells and LRP5ΔN-A 
or LacZ transfected cells were suggested within the same BMP2 concentration treatment group (* 
p<0.05). The result represents two independent experiments. Each experiment was carried out in 
triplicate. The error bars represent standard deviations. 
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Discussion 
 
In this study, a mutation of the LRP5 cytoplasmic domain corresponding to an SNP in the 
human population was investigated in the context of a constitutively active LRP5 molecule and 
shown to alter osteoblast differentiation in culture. This is the first observation of an LRP5 
cytoplasmic domain mutation affecting osteoblast differentiation and serves to underscore the 
significance of LRP5’s role in osteoblast biology. 
While there is apparent interest in the extracellular domain mutation of LRP5 (Ferrari et al 
2004; Koay et al 2004), there has been little attention paid to the less prevalent LRP5 SNPs 
affecting the cytoplasmic domain. The SNP p.V1525A (c.4574T>C) is particularly intriguing 
because 1) it is a cytoplasmic non-synonymous mutation, and 2) it is located adjacent to the 
putative Axin binding region. This SNP has a relatively low prevalence compared with other 
reported LRP5 SNPs (Koay et al 2004; Koh et al 2004; Toomes et al 2004). However, there exists 
a controversy regarding which nucleotide is predominant. The recorded full length sequences for 
LRP5 most frequently record nucleotide 4574 as T. Toomes et al (2004) first reported the 
presence of this SNP with 99% prevalence of T and 1% prevalence of C (Toomes et al 2004). In 
contrast, Koay et al (2004) reported less than 5% prevalence of T among 909 individuals of 
British white descent (Koay et al 2004). Our evaluation of the EST database indicated a high 
frequency of unique annotations with nucleotide 4574 encoding C. The relationship of this 
particular mutation with BMD or other osseous phenotypes is presently not defined. Further 
population evaluation may better define the potential significance of the mutation examined here. 
Expression of the non-synonymous mutation (p.V1525A) resulted in greater osteoblastic 
differentiation as revealed by early (ALP expression), intermediate (extended and elevated BSP 
expression) and terminal (mineralization of nodules) differentiation events. In contrast to these 
changes in differentiation, LRP5-mediated changes in cell proliferation or colony formation were 
not observed. 
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This finding extends previous reports performed using this constitutively active LRP5 
strategy. Liu et al (2003) demonstrated that LRP5 lacking the extracellular domain functioned 
independently of Wnt ligands and the FZD co-receptor and further demonstrated that its 
expression was associated with stabilization of β-catenin and increased TCF/LEF-mediated 
transcription (Liu et al 2003). This report also reiterates physiologic consequences of LRP5 
signaling, namely, osteoblastic differentiation. Based on current understanding of LRP5/FZD 
signaling and the role of Kremen and associated modulating ligands (Dickkopf and soluble 
frizzled related proteins), the present data suggests that LRP5 activity, irrespective of FZD 
function; or LRP ligands or antagonists, have important consequences in osteoblastic 
differentiation.    
This interpretation that the constitutive activity of the LRP5 construct led to increased 
osteoblastic differentiation is congruent with other data related to Wnt signaling. For example, 
Wnt-3A, a ligand for Lrp5 and Fzd co-receptors, is able to induce C3H10T1/2 osteoblastic 
differentiation that is effectively blocked by the Lrp5 antagonist Dickkopf-1 (Winkler et al 2005). 
Lithium Chloride treatment of cells mimics LRP5 signaling by inducing β-catenin stabilization 
and signal transduction that also enhances ectopic bone formation by human mesenchymal stem 
cells (hMSCs) (De Boer Wang and Van Blitterswijk 2004). Additionally, LRP5 mutations are 
associated with high bone mass or osteoporosis phenotypes in human population (Gong et al 2001; 
Little et al 2002). Thus, cell culture, animal study, and human genetic data strongly implicate 
LRP5 in positive control of bone mass and suggest the role(s) of LRP5 be considered broadly. 
Culture of the MC3T3-E1 cell in media supplemented with ascorbic acid and β-
glcyerolphosphate for 21-30 days results in the formation of bone-like nodules (Sudo et al 1983). 
During the development of multilayered nodules, the cells develop the ability to express ALP, 
BSP and OCN. This expression of BSP was modestly elevated by expression of LRP5 and 
sustained during the culture period. While LRP5 did modulate induced differentiation, it is also 
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important to recognize that LRP5 transfected cells were not capable of differentiation in the 
absence of culture supplements (not shown).  
Osteoblastic protein expression is directly influenced by the Runx2 and Osterix transcription 
factors (Komori 2002). The evaluation of Runx2 and Osterix mRNA abundance revealed no 
changes during osteoblast differentiation when either two forms of LRP5 SNPs were expressed. 
Thus, it is likely that the effects of LRP5 may be mediated through different target genes or 
alternative parallel pathways affecting osteogenesis.  
Since gene expression profiling indicated that LRP5∆N expression did not affect Runx2 and 
Osterix expression, alternative explanations for the increased differentiation were considered. To 
begin to understand whether effects of LRP5 could be mediated by interaction with the BMP 
pathway, the effect of LRP5 expression on BMP reporter gene expression was studied in a 
transient transfection assay. The higher level of SBE-luc activity in the LRP5∆N-V co-transfected 
cells is consistent with the greater osteoblastic differentiation of the LRP5∆N-V expressing 
cultures. The elevation of BMP reporter gene expression in LRP5∆N but not empty vector or 
LRP5∆N-A transfected cells suggests the presence of currently undefined crosstalk between the 
activin receptor-like kinase (ALK; bone morphogenic protein receptor) and LRP5 signaling 
pathways. The clinical significance of these biological observations may be further interwoven by 
the genetic relationships among BMP-2, LRP5 and bone mass.  
In conclusion, a constitutively active LRP5 construct functions in the promotion of 
osteoblastic differentiation. A cytoplasmic mutation identified in the SNP database is associated 
with increased osteoblastic differentiation under conditions of constitutive activity. These 
findings are consistent with and contribute to the understanding of LRP5 as a Runx2-pathway 
independent mediator of bone mass. LRP5 pathway interaction with BMP-mediated signaling 
merits further investigation. 
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CHAPTER III 
 
Identification of Genes that Control the Phenotype of Wnt5a-deficient Mouse 
Calvarial Cells  
Abstract 
 Wnts (wingless and int-related proteins) are a family of secreted cysteine-rich glycoproteins, 
expressed in a variety of tissues in developing embryos, thought to be involved in cell fate specification 
and stem cell commitment. To identify the specific Wnts involved in osteoblastic differentiation of human 
mesenchymal stem cells (hMSCs), we performed degenerative RT-PCR cloning method to amplify Wnt-
encoding cDNAs expressed during osteoblastic differentiation of hMSCs in vitro and during hMSC-
directed ectopic osteogenesis in the severe combined immunodeficient (SCID) mouse host. Wnt5a was 
found to be the dominant Wnt expressed during osteoblastic differentiation of hMSCs both in vitro and in 
vivo. RT-PCR further revealed that hWNT5A and its receptor Frizzled family member 5 (hFZD5) was up-
regulated during osteoblastic differentiation compared to uncommitted hMSCs. To evaluate the function 
of Wnt5a in osteoprogenitor cells, calvarial cells were obtained from Wnt5a-/-, Wnt5a+/-, and wild type 
mice. Wnt5a-/- cells showed significantly slower cell proliferation when compared to Wnt5a+/- and wild 
type cells. Gene expression profiles of the Wnt5a-/- calvarial cells as compared to wild type cells were 
evaluated using microarray analysis. 255 genes exhibited at least 2-fold changes in expression. In addition, 
genes regulating osteoblastic differentiation including Runx2, osterix, and alkaline phosphatase (ALP) 
were shown to be down-regulated in Wnt5a-/- cells. In conclusion, Wnt5a expression occurs in lineage 
specific manner. The knock-out model suggests a role for Wnt5a signaling during osteogenesis. Knock-
out cells reveal Wnt5a expression affects cell cycle progression and is required for cell growth.  
 
Introduction 
 
 Osteoblastic differentiation is a complex process involving a variety of signaling molecules. 
Prominent among them are the bone morphogenic protein (BMP)-mediated signals, runt-related 
transcription factor 2 (Runx2) regulation of gene expression and osterix directed transcription (Ducy et al 
1997; Komori et al 1997; Nakashima et al 2002; Otto et al 1997; Skillington Choy and Derynck 2002). In 
addition, numerous growth factors as well as systemic hormones play important roles in the definition of 
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the osteoblast phenotype (Aubin and Bonnelye 2000). Developmental signaling in limb as well as 
craniofacial development invokes signals from a wider range of molecules including msh homeobox 
(MSX), distal-less homeobox (DLX) and wingless-type MMTV integration site family (Wnt) members 
(Carlson Bryant and Gardiner 1998; Church and Francis-West 2002; Robledo et al 2002). 
The Wnt secreted proteins are a family of cysteine-rich glycoproteins that regulate embryonic 
development, cell differentiation, proliferation, and migration. (Brandon Eisenberg and Eisenberg 2000; 
Church and Francis-West 2002; Li et al 2002; Lickert et al 2001). Wnt signaling is initiated by binding to 
two receptors: the Frizzled family (FZD) and the lipoprotein receptor-related proteins 5 or 6 (LRP5/6). 
The Wnt ligands are divided into two categories based on the downstream mediated signaling. The 
canonical Wnts are β-catenin-dependent, including Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8 and Wnt8b (Katoh 
2002). The other class is the so-called “non-canonical” Wnts such as Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, 
and Wnt11, which function independently of or inhibit β-catenin signaling (Church and Francis-West 
2002; Katoh 2002). 
The well-understood canonical Wnt signaling pathway is mediated by β-catenin activity. In the 
absence of a Wnt ligand, β-catenin, is bound in a cytosolic protein complex containing Axin, 
adenomatous polyposis coli gene product (APC), glycogen synthase kinase-3β (GSK-3β), and other 
proteins. Thereby, it is ubiquitinated by β-transducin repeat-containing homologue protein (βTrCP) and 
degraded in the proteasome. Binding of Wnt protein to Frizzled (FZD) and LRP5/6 coreceptors leads to 
the activation of Dishevelled (DVL) protein, which then inhibits GSK-3β-mediated phosphorylation of β-
catenin. Cytosolic β-catenin is then released from the protein complex and translocated into nucleus, 
where it binds to T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors and leads to 
activation of the target gene expression (Gordon and Nusse 2006; Nusse 2005; Reya and Clevers 2005). 
These target genes consequently affect cell behavior. Some of the target genes also have feedback effects 
on the Wnt/β-catenin signaling and regulate cell-cell communication 
(http://www.stanford.edu/~rnusse/wntwindow.html).  
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Two β-catenin-independent pathways have been demonstrated previously. Some Wnts signal via 
the small GTPases Rho and Cdc42 to c-Jun N-terminal kinase (JNK) (Boutros et al 1998; Ryu and Chun 
2006; Yamanaka et al 2002). Other Wnts can stimulate the release of intracellular Ca2+, activating protein 
kinase C (PKC), nuclear factor associated with T cells (NFAT) and Ca2+/calmodulin-dependent kinase II 
(CamkII) (Kuhl et al 2000; Sheldahl et al 1999). Wnt5a has been shown to signal through both the 
Wnt/JNK pathway and the Wnt/Ca2+ pathway (Kuhl et al 2000; Ryu and Chun 2006; Yamanaka et al 
2002). 
Wnt expression in development is particularly interesting because it appears to function in control 
of cell fate specification and stem cell commitment. Wnt5a and Wnt11 modulate the diversification of 
hematopoietic progenitor cells (Austin et al 1997; Brandon Eisenberg and Eisenberg 2000; Lako et al 
2001). Wnt10b signaling was indicated to serve as a molecular switch that governs adipogenesis. 
Disruption of Wnt signaling caused the transdifferentiation of adipocytes to myoblasts in vitro (Ross et al 
2000). Inhibition of Wnt signaling can predispose mesenchymal stem cells (MSCs) to cell cycle entry and 
inhibition of osteogenesis (Gregory et al 2003; Gregory et al 2005). Limb developmental research has 
further suggested the prominent role of Wnt signaling in mesenchymal stem cell fate (Chimal-Monroy et 
al 2002; Church and Francis-West 2002; Hartmann and Tabin 2000).  
 Given the acknowledged role of the mesenchymal stem cells (MSCs) in the multipotential 
generation of tissue forming cells, the possible role of Wnt signaling leading to MSCs commitment and 
differentiation should be defined. In the current study, we have demonstrated the unique expression 
pattern of Wnt5a during hMSCs differentiation along the osteoblastic lineage. The potential role of Wnt5a 
in cell cycle regulation of osteoprogenitor cells was further suggested by the molecular phenotype of 
calvaria-derived cells from Wnt5a-/- mice.  
 
Materials and methods 
 
In vitro hMSCs differentiation  
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 Human MSCs were obtained from iliac crest bone marrow aspirates provided from 4 donors, 
under the Institutional Review Board (IRB) approved informed consent using procedures previously 
described in detail (Jaiswal et al 1997; Pittenger et al 1999). Expanded cells were cryopreserved and 
subsequently thawed and grown to confluence in 150 mm2 dishes. The cells were then split once, and 
plated into 100 mm2 dishes in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal 
bovine serum (FBS). 
Cells were grown to confluence (Day 0) and then induced to differentiate along the osteogenic, 
adipogenic and chondrogenic lineages using the corresponding established induction assay (Jaiswal et al 
1997; Pittenger et al 1999). For osteoblastic differentiation, cells were treated with osteogenic 
supplemented (OS) medium containing 0.1 μM dexamethasone, 0.05 mM ascorbic acid, and 10 mM β-
glycerophosphate in addition to DMEM-low glucose, 10% FBS and antibiotics. Cells were cultured for 1-
14 days with OS medium change every other day.  
Adipogenic differentiation was stimulated by three cycles of induction/maintenance (Janderova et 
al 2003; Pittenger et al 1999). Each cycle consisted of three days of induction by feeding cells with 
adipogenic induction medium (containing 1 μM dexamethasone, 0.2 mM indomethacin, 0.01 mg/ml 
insulin, 0.5 mM 3-isobutyl-1-methyl-xanthine in addition to DMEM-high glucose, and 10% FBS) for 3 
days, followed by 2 days of culture in adipogenic maintenance medium (containing 0.01 mg/ml insulin in 
addition to DMEM-high glucose, and 10% FBS).  
The micromass culture system was applied to induce chondrogenic differentiation (Mackay et al 
1998). 2.5 x 105 cells were pelleted and cultured in 14 ml Falcon tubes by feeding with chondrogenic 
induction medium (containing 0.1 μM dexamethasone, 1 mM sodium pyruvate, 0.17 mM ascorbic acid, 
0.35 mM proline, 6.25 μg/ml bovine insulin, 6.25 μg/ml transferrin, 6.25 μg/ml selenous acid, 5.33 μg/ml 
linoleic acid, 1.25 mg/ml bovine serium albulim (BSA) and 0.01 μg/ml TGF-β3 in addition to DMEM-
high glucose and 10% FBS). Cells were cultured for 1-14 days with replacing medium ever other day. 
 
In vivo osteoblastic differentiation of hMSCs  
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 An ectopic model of bone formation was employed (Cooper et al 2001). Human MSCs were 
cultured in the DMEM containing 10% FBS. Upon confluence, cells were loaded into 3 mm 
hydroxyapatite tricalcium phosphate (HA/TCP) cubes, and implanted subcutaneously in severe combined 
immunodeficient (SCID) mice for ectopic bone formation. After 3-14 days, the implants were harvested, 
and frozen in liquid nitrogen for RNA extraction. 
 
RNA extraction and degenerate RT-PCR 
 Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA), followed by DNase 
treatment (Clontech, Palo Alto, CA).  Messenger RNAs were reverse transcribed to cDNA using 
Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA). The implicated Wnt genes were then 
amplified by degenerate PCR using HotStarTaq DNA Polymerase (Qiagen, Valencia, CA). The 
degenerate primers were designed to have the ability to amplify all 19 members of human Wnts (Forward 
primer: nnn gtc gac gct tgy aar tgy cay gg; Reverse primer: nnn gtt aac tac gtr rca rca cca rtg). PCR 
products were purified using Qiaquick PCR purification microcentrifuge kit (Qiagen, Valencia, CA), and 
then cloned into pCR2.1 vector using TA cloning kit (Invitrogen, Carlsbad, CA). 
 
DNA sequence analysis and clone screening 
 Plasmids with inserts were purified using Qiaquick mini-prep kit (Qiagen, Valencia, CA). 
29 cDNA clones from in vitro osteoblastic differentiated samples and 26 cDNA clones from in 
vivo samples were sequenced by the UNC-CH Automated DNA Sequencing Facility using the 
M13R primer. 
96 more DNA clones (50 from in vitro osteoblastic differentiated samples and 46 from in vivo 
differentiated samples) were purified using the same method and digested by EcoRI. Digested plasmids 
were separated on 1% agarose gel, and transferred to nylon membranes, which were then hybridized with 
33P-labelled hWnt5a probe. The Wnt5a probe was amplified from purified pCR2.1/hWnt5a plasmid by 
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PCR using M13R/F primer pairs, and labeled with α33P-dCTP using RediprimeTM II Random Prime 
Labeling System (Amersham Biosciences, Piscataway, NJ).  
 
RT-PCR analysis of gene expression of identified Wnts and lineage specific markers 
 Reverse transcribed cDNAs were amplified using HotStarTaq DNA Ploymerase (Qiagen, 
Valencia, CA). The amplified products were then separated by 1% agarose gel electrophoresis. The 
corresponding PCR primer pairs of WNT5A, WNT3, WNT2B, bone sialoprotein (BSP), peroxisome 
proliferator activated receptor γ (PPARγ), collagen II A1 (COL2A1), hFZD5, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) are shown in Table 1. The PCR product yields were quantified using 
LumiImager. Relative expression levels of transcripts of interest were analyzed after normalization by the 
corresponding GAPDH yields.   
 
Animals 
 Wnt5a heterozygous (Wnt5a+/-) mice were obtained from Dr. Yingzi Yang (NIH, National 
Human Genome Research Institute, Bethesda, MD). All experiments were performed using E19 embryos. 
The genotypes of the wild type (Wt), Wnt5a+/-, and Wnt5a-/- mice were determined using combination of 
primers containing 5’ GGG AGC CGG TTG GCG CTA CCG GTG G 3’, 5’ GAC TTC CTG GTG AGG 
GTG CGT G 3’, and 5’ GGA GAA TGG GCA CAC AGA ATC AAC 3’ in a standard PCR reaction. 
PCR results were resolved by electrophorosis through 1% agarose gels, yielding a 200 bp null band and a 
350 bp wild type band, representing the wild type and the Wnt5a-/- alleles respectively.  
  
Preparation of murine calvarial cells 
 Murine calvarial cells were prepared and cultured using the modifications of the method of 
Komaki et al (Komaki Katagiri and Suda 1996). Calvariae harvested from E19 embryos were washed 
twice in complete culture medium (MEM supplemented with 10% FBS and 100 units/ml 
 65
penicillin/streptomycin). The calvariae were then cut into pieces and cultured in the complete medium for 
3 days. Non-adherent cells were then removed by washing with PBS for three times. The adherent cells 
enriched in osteoprogenitor cells were sub-cultured (passage=1) for 5 days in all three groups for the 
subsequent assays.  
 
Microarray 
 The cells from wild type and Wnt5a-/- mouse calvariae were collected from the sub-cultures. Total 
RNAs were isolated using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacture’s 
protocol. The RNA was quantitated by measuring the ultraviolet absorption at the 260 nm using a 
Beckman DU-600 and adjusted to 1.0 μg/μl using RNase-free water. The RNA quality was analyzed 
using an Agilent LabChip Bioanalyzer. 14 μg of total RNAs from the wild type and Wnt5a-/- cells were 
reverse transcribed into single-stranded cDNA using SuperScript II reverse transcriptase (Invitrogen) and 
labeled with Cy3 and Cy5 dyes respectively. The labeled cDNAs from wild type and Wnt5a-/- samples 
were combined and purified using QIAquick PCR purification kit (Qiagen, Valencia, CA). After 
concentrated using a Microcon-30 column (Milipore, Bedford, MA), the cDNA combination was then 
hybridized to an Agilent mouse oligo microarray (Product #: G4121A) displaying 60-mer oligonucleotide 
probes representing over 20,000 well-characterized mouse genes for 16 hrs at 65oC. Arrays were washed 
in 2X SSC, 0.1% SDS for 4 min, 1X SSC, 0.1% SDS for 4 min, 0.2X SSC for 4 min, 0.05X SSC 
for 1 min and air dried. Hybridization signal was visualized and collected using an Axon 
microarray scanner and GenePix Pro software. The microarray experiments were performed in triplicate. 
 
Data analysis 
 For microarrays, data were analyzed using a combination of three different software tools, 
including Significance Analysis of Microarrays (SAM), linear models for microarray data (limma) in 
BioConductor, and GeneSpring GX (Agilent Technologies, Palo Alto, CA). After reading the data, the 
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output from Genepix analysis, into R/Bioconductor, the “normexp” algorithm for foreground signal 
correction and “loess” were applied for within array normalization (Smyth Michaud and Scott 2005). The 
one class test of “samr” (Bioconductor) with false discovery rate equal to 5% was applied to determine 
differentially expressed genes in Wnt5a-/- versus wild-type calvarial cells (Tusher Tibshirani and Chu 
2001). The genes in the resulting list showing greater than/equal to 1.2-fold up- or down- regulation were 
kept. Simple comparison of the knock-out versus wild-type control using the loess normalized data 
described previously and the default multiple test correction method were performed with limma analysis. 
In GeneSpring GX, the raw data were processed by “per spot and per chip: intensity dependent (Lowess) 
normalization”.  
 Several criteria were employed to filter out a starting list of genes for statistical analysis. The 
probe sets that were used for analysis must have flags of “present” at least in two out of three samples; 
The genes that displayed less than 1.2 fold change in gene expression levels between the knock-out and 
wild-type calvarial cells were removed as well before statistical analysis. The resulting p-values were 
corrected using Benjamini & Hochberger false discovery rate and the cutoff of p-value was 0.05.   
 For Wnt clone screening, we used binomial distribution to calculate p-values. For gene ontology 
and pathway analysis, we applied the GO Ontology Browser function, KEGG pathway package, mmu, 
from http://www.genome.jp/kegg, and Biological Pathway analysis script in GeneSpring GX. The raw p-
values measured in both the GO and pathway analyses were corrected using Benjamini & Hochberg false 
discovery rate method (Benjamini et al 2001). To estimate association between the result from RT-PCR 
and the one from microarray we explored the Pearson method to measure correlation coefficient. 
   
Quantitative Real-time PCR 
 For validation of microarray data, quantitative real-time PCR was used to measure changes in 
gene expression. The total RNA was harvested from cultured cells isolated from additional Wnt5a-/- or 
Wnt5a+/-mouse calvaria and prepared independently from those used for the microarray experiments. One 
microgram of the total RNA was reverse transcribed using SuperScript II reverse transcriptase 
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(Invitrogen). FAM dye-labeled mouse cyclin G1 (Ccng1; ABI assay No. Mm00438084_m1), 
retinoblastoma 1 (Rb1; ABI assay No. Mm00485586_m1), follistatin (Fst; ABI assay No. 
Mm00514982_m1), Wnt1 inducible signaling pathway protein 1 (Wisp1, ABI assay No. 
Mm00457574_m1), secreted frizzled-related protein 2 (Sfrp2; ABI assay No. Mm00485986_m1), Runx2 
(ABI assay No. Mm00501578_ml), Osterix (ABI assay No. Mm00504574_ml), Alp (ABI assay No. 
Mm00475831_m1), Col2a1 (ABI assay No. Mm00491889_m1), insulin growth factor 2 (Igf2; ABI assay 
No. Mm00439564_m1), desert hedgehog (Dhh; ABI assay No. Mm00432820_g1), and VIC dye-labeled 
rodent G3pdh (ABI assay No. 4308313) were amplified using TaqMan Universal PCR Master Mix 
(Applied Biosystems, Foster city, CA). Results were analyzed using the Applied Biosystems 7000 Real-
Time PCR System software. Messenger RNA levels of the tested genes relative to Gapdh were 
determined and the fold changes were calculated using the values of undifferentiated samples (day 0) as 
the calibrators by means of 2-ΔΔCt method (Livak and Schmittgen 2001). 
 To quantify the expression of WNTs during osteogenic, adipogenic, and chondrogenic 
differentiation of hMSCs, real-time RT-PCR was performed using human WNT5A (ABI assay No. 
Hs00180103_m1), WNT3 (ABI assay No. Hs00229135_m1), and WNT2B (ABI assay No. 
Hs00244632_m1) as primers. Results were analyzed as above.   
 
Cell proliferation assay 
 Mouse calvarial cells (passage one) obtained from wild type, Wnt5a+/-, and Wnt5a-/- mice were 
seeded onto 12-well tissue culture plates (5,000 cells / well) in quintuplicate and cultured in the MEM 
complete medium. Five days after the initial seeding, cell cultures were visualized under microscope 
(Olympus). Cell growth was evaluated using liquid crystal violet assay. Cell layers in the culture plates 
were washed twice with 1x PBS, fixed in 4% paraformaldehyde in 1x PBS for 1 hr, and then stained with 
1.0% crystal violet in 1x PBS for 2 hrs. After washing with 1x PBS for 2 hrs with shaking to remove the 
background staining, the cell layers were then destained in 1.0% SDS for 30 min with constant shaking. 
The supernatants were then transferred to a translucent 96-well plate and the absorption at 570 nm was 
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recorded using BioRad microplate reader (Sarray et al 2004). The assay was done in triplicates and 
repeated once. The average of all six results was plotted. 
 
Results 
 
WNT expression pattern during osteoblastic differentiation of hMSCs 
The successful hMSC differentiation along the osteogenic, adipogenic and chondrogenic lineage 
was verified by RT-PCR of the corresponding markers: BSP for osteoblastic, PPARγ for adipogenic and 
COL2A1 for chondrogenic differentiation (Fig. 9). The final results of differentiation along different 
pathways were also confirmed with the formation of bone nodules in osteogenesis by alizarin red staining; 
lipid droplets in adipogenesis by oid O red staining; and chondrogenic pallets in chondrogenesis (data not 
shown). In this study, hMSCs from three different donors (#102, #157, and #547) were used for the in 
vitro study. The cells from all the donors were pre-tested for osteogenic, adipogenic, and chondrogenic 
differentiation markers. 
Degenerate RT-PCR cloning identified WNT5A, WNT3, and WNT2B mRNAs from the 
osteoblastic differentiated hMSCs (3, 7, and 14 days after OS treatment; Table 3). Of the 29 clones 
sequenced from three different donors, 28 clones were WNT5A and one (from the 7 day OS treatment of 
the donor #547 hMSCs) was WNT3 (Table 3A). To confirm the dominant WNT5A expression, additional 
50 clones were further analyzed by southern blotting of WNT5A encoding cDNAs. 49 clones were found 
to be WNT5A, and the remaining clone was identified as WNT2B by automatic DNA sequencing (Table 
3B).  
The relative expression levels of WNT5A, WNT3 and WNT2B were further examined during the 
first 14 days of in vitro osteogenic, adipogenic and chondrogenic differentiation by RT-PCR (Fig. 10). 
After 25 cycles of amplification, the PCR results revealed moderate expression of WNT5A during 
osteogenic and adipogenic differentiation of hMSCs. Relative low level of WNT5A expression was 
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observed during chondrogenic differentiation. These findings were subsequently quantified using real-
time RT-PCR. The modestly increased (approximately 2 fold) levels of WNT5A during osteogenic 
induction are contrasted to the marked reduction in WNT5A levels during chondrogenic induction. A 
threshold cycle (Ct) range of 24 ~ 26 was noted for both GAPDH and Wnt5A. As indicated by the 
qualitative assessment, the hMSC expression of Wnt3 and Wnt2B was low and observed at threshold 
cycles of more than 34-35. In contrast to Wnt5A, the modest fold-induction observed for these WNTs is 
underscored by low basal expression (Fig. 10). In addition to the up-regulation of Wnt5a during 
osteogenesis, hFZD5, the putative receptor of Wnt5a, was also detected and shared the similar expression 
pattern with Wnt5a in osteogenic differentiation pathway (Fig. 11). 
Tissues formed in vivo 14 days following implantation of hMSCs adherent to HA/TCP scaffolds 
into SCID mice contained human WNT5A, mouse Wnt11 and mouse Wnt2 (Table 3). Out of 26 
sequenced clones, 24 clones were human WNT5A, and two were mouse Wnt2 (Table 3A). A human 
WNT5A Southern blot of additional 46 clones derived from this in vivo tissue demonstrated that human 
WNT5A was again the dominant Wnt mRNAs expressed by transplanted hMSCs. Thirty-eight of 46 
clones were found to be human WNT5A, and 1 mouse Wnt11 clone and 7 mouse Wnt2 clones were 
identified by sequence analysis of the remaining clones. (Table 3B) 
 
Cell morphology and cell proliferation of Wnt5a-/- osteoprogenitors 
 Mouse calvarial cells harvested from Wnt5a-/-, Wnt5a+/-, and wild type mice were cultured in 
complete medium until confluence. The passage one cells from Wnt5a-/- mice showed slower growth 
compared to cells from Wnt5a+/- and wild type mice, as demonstrated using the liquid crystal-violet assay 
(Fig. 12A). However, no significant difference was observed between the cells from Wnt5a+/- and wild 
type mice. Furthermore, the Wnt5a-/- cells were larger and more elongated in cell shape (suggestive of 
senescence) under microscopy as compared to cells from Wnt5a+/- and wild type cells (Fig. 12B). The 
results suggested that Wnt5a expression was required for proper growth of the calvaria-derived cells. 
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Global gene expression patterns for Wnt5a-/- osteoprogenitors 
 In order to identify the sets of genes controlling Wnt5a signaling, we determined the global gene 
expression patterns in Wnt5a-deficient mouse calvarial cells as compared to wild type mouse calvarial 
cells using microarray technology. The microarray experiment was conducted in triplicate using the 
pooled total RNAs from three Wnt5a-/- or wild type mice in order to minimize the experimental variations. 
The genes that displayed less than 1.2 fold change in gene expression levels between the knock-out and 
wild-type calvarial cells were removed before statistical analysis. Three different microarray analysis 
tools GeneSpring GX, the linear models for microarray data (limma) package, and SAM in Bioconductor, 
were applied for statistical analysis in order to minimize the drawbacks of the individual software. The 
resulting p-values were corrected using Benjamini & Hochberger false discovery rate and the cutoff of p-
value was 0.05. A list of 3528 common genes generated by using the three analytic tools were considered 
differentially expressed in Wnt5a-/- calvarial cells as compared to wild type cells. 1526 genes were down-
regulated and 2002 genes were up-regulated in Wnt5a-/- cells. The KEGG pathway analysis revealed that 
Wnt5a deficiency in mice calvarial cells altered MAPK signaling pathway, focal adhesion, regulation of 
actin cytoskeleton, Wnt signaling pathway, axon guidance, tight junction, cell cycle, ECM-receptor 
interaction, gap junction, apoptosis, adherens junction, biosynthesis of steroids, and terpenoid 
biosynthesis (Table 5, corrected p value ≤ 0.1). Gene ontology analysis of biological processes suggested 
that Wnt5a affected cell cycle, cellular physiological process, sterol biosynthesis, cell division, 
vasculature development, regulation of progression through cell cycle, blood vessel development, 
development, biopolymer metabolism, mitotic cell cycle, mRNA processing, cell proliferation, cellular 
morphogenesis, and sterol metabolism (Table 5, corrected p value ≤ 0.1).  
 Among the differentially expressed genes, 408 genes were found to have greater than or equal to 
2-fold changes in expression levels in all three separate experiments (205 up-regulated and 203 down-
regulated). Those genes were then dissected into subsets according to gene ontology biological process. 
Genes regulating cell cycle, cell proliferation or cell growth, skeletal development, and regulation of 
transcription are highlighted in table 6. Real-time PCR analysis was further performed to evaluate the 
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level of several selected genes expression using different sets of Wnt5a-/- and wild type calvarial cells. 
Person correlation test suggested good association between real-time PCR results and the microarray 
results (Table 7, correlation coefficient R=0.78, p<0.01).   
 Eleven genes involved in cell cycle regulation, including transformed mouse 3T3 cell double 
minute 2 (Mdm2), growth arrest and DNA-damage-inducible 45 gamma (Gadd45g), annexin A1 (Anxa1), 
retinoblastoma 1 (Rb1), RB1-inducible coiled-coil 1 (Rb1cc1), cyclin G (Ccng), dual specificity 
phosphatase 1 (Dusp1), Reprimo, TP53 dependent G2 arrest mediator candidate (Rprm), forkhead box G1 
(Foxg1), cyclin-dependent kinase 6 (Cdk6), S100 calcium binding protein A6 (calcyclin), and protein 
phosphatase 3 were up-regulated > 2 fold in Wnt5a deficient cells (Table 6). Genes including insulin-like 
growth factor 2 (Igf2), mini chromosome maintenance deficient 6 (Mcmd6), fibroblast growth factor 2 
(Fgf2), transforming growth factor alpha (Tgfα), growth arrest specific 1 (Gas1), regulator of G-protein 
signaling 2 (Rgs2), cell division cycle 20 homolog, sestrin 2 (Ses2), growth arrest specific 2 (Gas2), and 
Mcmd2 were down-regulated > 2 fold (Table 6). The expression levels of Rb1 and Ccng1 were further 
confirmed using real-time PCR, showing 2.6 and 2.1 fold induction respectively in Wnt5a-/- calvarial cells 
as compared to wild type cells (Fig. 13).   
 Twenty-six genes controlling cell proliferation and cell growth were shown to be up- or down- 
regulated > 2 fold in Wnt5a-/- cells (Table 6). The down-regulated genes include Igf2, endothelial 
differentiation, sphingolipid G-protein-coupled receptor, 3 (Edg3), insulin-like growth factor binding 
protein 4 (Igfbp4), Fgf2, Tgfα, nephroblastoma overexpressed gene (Nov), growth differentiation factor 
10 (Gdf10), latent transforming growth factor beta binding protein 4 (Ltbp4), growth factor receptor 
bound protein 10, 7-dehydrocholesterol reductase (Dhcr7), protease, serine, 11 (Igf binding) (Prss11), and 
stem cell growth factor (Scgf). The up-regulated genes include caveolin 2 (Cav2), inhibin beta-A, 
caveolin 1 (Cav1), Igfbp7, Igf1, heparin-binding EGF-like growth factor (Hbefg), Fgf9, annexin A1 
(Anxa1), COP9 (constitutive photomorphogenic) homolog, subunit 2 (Cops2), calcyclin, cysteine rich 
protein 2 (Crip2), interleukin 7 (Il7), nerve growth factor, beta (Ngfβ), and epithelial membrane protein 1 
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(Emp1). Among these genes, insulin-like growth factor 2 was down-regulated 6.54 fold, which was also 
confirmed by real-time PCR showing 11-fold reduction in Wnt5a-/- cells (Fig. 13). 
 Among all the regulated genes, desert hedgehog (Dhh) was shown to be down-regulated 17 fold 
in the Wnt5a-/- osteoprogenitor cells when compared to wild type cells. Gas1, a glycosylphosphatidyl-
inositol (GPI)-linked membrane protein known to interact with hedgehog, was down-regulated 2.76 fold. 
Several Forkhead box (Fox) transcription factors including FoxC1, FoxC2, FoxD1, and FoxG1 that are 
hedgehog target genes were also down-regulated (Table 6). Expression levels of Indian hedgehog (Ihh) 
and Sonic hedgehog (Shh) were evaluated using real-time PCR, showing 1.5-fold induction of Shh in 
Wnt5a-/- cells when compared to wild type cells. However, Ihh expression levels were low in both Wnt5a-
/- and wild type cells (Ct value > 35, data not shown).  
 Thirty-nine canonical Wnt signaling pathway related genes were altered by knocking out Wnt5a 
expression (Table 4). 25 of the canonical Wnt signaling pathway related genes were listed in table 8. 
Among the altered Wnt signaling regulators, secreted frizzled 2 (Sfrp2), the inhibitor of canonical Wnt 
signaling pathway, was down-regulated 2.72 fold. Wnt1 inducible signaling pathway protein 1 (Wisp1) 
was up-regulated approximately 2 fold (Table 6). The expression level of both genes was also confirmed 
by real-time PCR (Fig. 13).  
 Twenty-five genes involved in skeletal development were regulated >2 fold in Wnt5a-/- cells. 
Several involve processes of collagen biosynthesis, among which lysyl oxidase (Lox), procollagen lysine, 
2-oxoglutarate 5-dioxygenase 2 (Plod2), alpha 3 binding protein (Col4a3b), and procollagen, type IV are 
up-regulated; procollagen, type II, alpha 1 (Col2a1), procollagen, type VII, alpha 1 (Col7a1), procollagen 
C-proteinase enhancer protein (Pcolce), hypothetical Fibronectin type III domain containing protein, 
Col14a1, Col6a1, and matrix gamma-carboxyglutamate (gla) protein are down-regulated. Others reflect 
regulatory pathways implicated in osteogenesis, including down-regulated genes such as Follistatin (Fst), 
periostin, tissue inhibitor of metalloproteinase 3 (Timp3), integrin alpha 6, a disintegrin and 
metalloproteinase domain 9 (meltrin gamma) (Adam9), BMP-binding endothelial regulator (Bmper), and 
secreted phosphoprotein 1 (Spp1); and down-regulated genes such as Igf2,  Tgfbi, a disintegrin-like and 
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metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2 (Adamts2), Igfbp4, Gdf10, 
apolipoprotein E (Apoe), SPARC related modular calcium binding 1 (Smoc1), and Smoc2 (Table 6). 
 Genes involved in osteoblastic differentiation were further evaluated using real-time PCR, 
showing down-regulation of Runx2, Osterix, Col2a1, and alkaline phosphatase (ALP) in Wnt5a-/- 
osteoprogenitor cells, and up-regulation of Fst, a BMP signaling inhibitor (Fig. 13).  
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Table 2.    
PCR oligonucleotide primer sequences and sizes of expected amplification products 
Primer Name Sequence (5’-3’) 
Size 
(bp) 
Forward CTGCAGCACTGTGGATAACACCT 
Wnt5a Reverse TGTCGTACTTCTCCTTCAGGGCAT 
449 
Forward GCGCTCGGCCATGAACAAGCACA 
Wnt3 Reverse CCGGTCCCTTGTGCCAAAGGAACC 
325 
Forward GATCCACGCTATTACTCGCGCCTGTAG 
Wnt2b Reverse TCTTGGGTGGCCATCACCTGCACA 
366 
Forward TGGTATCGTGGAAGGACTCATGAC 
G3PDH Reverse ATGCCAGTGAGCTTCCCGTTCAGC 
189 
Forward GCTCAGCATTTTGGGAATGGC 
BSP Reverse CTGCATTGGCTCCAGTGACAC 
614 
Forward AAGATGGTCCCAAAGGTGCTCG 
COL2A1 Reverse AGCTTCTCCTCTGTCTCCTTGC 
500 
Forward GTTCATGCTTGTGAAGGATGC 
PPARγ Reverse ACTCTGGATTCAGCTGGTCG 
249 
Forward CCGTCCTTCAGTGCCGACGA 
FZD5 Reverse TCAGGTTCTGGTTGCCCACGTA 
498 
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Table 3. Degenerate Wnt RT-PCR results. A) Human MSCs were differentiated into osteoblasts in 
vitro or in vivo. Degenerate Wnt RT-PCR was conducted, and the PCR products were inserted into 
pCR2.1 vector. The vector with inserts were cloned and sequenced by automatic DNA sequencing 
strategy using M13R primer. The obtained sequences were blasted by NCBI database and identity of 
Wnts assigned as shown. B) The in vitro and in vivo clones were digested by EcoR1 at 37oC for 2 hours. 
Digested cDNAs were separated on 1% agarose gel, and transferred to nylon membrane. The membrane 
was then hybridized with 33P-labelled human Wnt5a probe and exposed to Phosphoimager for 24 hours. 
The non-hWnt5a clones were defined by automatic DNA sequencing strategy. The probabilities of 
obtaining Wnt5a in all clones/Southern blotting were calculated using binomial test with hypothesized 
probability of success as 1/19. 
Table 3A.   
DNA sequencing results of degenerate Wnt RT-PCR products 
Samples In Vitro In Vivo 
Clones 29 26 
Human Wnt5a 28 24 
Human Wnt3 1 - 
MouseWnt2 - 2 
P-value ~0 ~0 
   
Table 3B.   
Southern Blotting results of degenerate Wnt RT-PCR products 
Samples In vitro  In vivo 
Clones 50 46 
Human Wnt5a 49 38 
Human Wnt2b 1 - 
MouseWnt2 - 7 
Mouse Wnt11 - 1 
P-value ~0 ~0 
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Table 4. KEGG pathway analysis of the microarry results. The bioscript, SG3b-1 – Find genes in a 
GL present in PATHWAYS, of GeneSpring GX  and KEGG pathways (http://www.genome.jp/kegg/) 
were used for pathway analysis. The genes for this analysis were ones which are common in the three 
methods described in materials and methods. The p-values were corrected with the Benjamini & 
Hochberg false discovery rate method versus the total 175 pathways for the analysis.  
Table 4: KEGG pathway analysis    
KEGG Pathways  
Number of genes 
in list within each 
pathway 
Gene List vs 
Pathway random 
overlap p-value 
p-
value_fdr_BH 
 MAPK signaling pathway  84 1.33E-06 6.52E-05 
 Focal adhesion  73 4.69E-10 6.89E-08 
 Regulation of actin cytoskeleton  68 3.95E-07 2.90E-05 
 Wnt signaling pathway  39 0.0105 0.1029 
 Axon guidance  38 0.00537 0.071762727 
 Tight junction 37 0.000199 0.004179 
 Cell cycle  35 0.000156 0.003822 
 ECM-receptor interaction  33 1.86E-05 6.84E-04 
 Gap junction 29 0.00446 0.065562 
 Apoptosis 26 0.00366 0.05978 
 Adherens junction  24 0.0095 0.09975 
 Biosynthesis of steroids 11 3.07E-05 9.03E-04 
 Terpenoid biosynthesis 5 0.000703 0.012917625 
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Table 5. Gene ontology (based on biological process) analysis of the microarray results. The Gene 
Ontology Browser function in GeneSpring GX was applied for the analysis. The genes used are ones 
which are overlapped in the resulting lists from three separate analytic methods as described in Materials 
& Methods. The p-values are corrected with Benjamini & Hochberg false discovery rate method with the 
total 10056 categories of Biological Processes used in this study. 
Table 5: Gene ontology analysis based on biological analysis  
Category Genes in Category 
% of 
Genes in 
Category 
Genes in 
List in 
Category 
% of Genes in 
List in 
Category 
p-
val_fdr_BH 
cell cycle 546 4.946 151 7.116 0.00180206 
cellular physiological 
process 8139 73.73 1640 77.29 0.02470065 
sterol biosynthesis 24 0.217 14 0.66 0.0260988 
cell division 167 1.513 54 2.545 0.02664253 
vasculature development 118 1.069 41 1.932 0.02976506 
regulation of progression 
through cell cycle 277 2.509 80 3.77 0.02863618 
blood vessel development 116 1.051 40 1.885 0.03173579 
development 1742 15.78 393 18.52 0.03289536 
biopolymer metabolism 2104 19.06 466 21.96 0.03624833 
mitotic cell cycle 156 1.413 49 2.309 0.0537511 
mRNA processing 238 2.156 68 3.205 0.07739255 
cell proliferation 278 2.518 77 3.629 0.083889 
cellular morphogenesis 311 2.817 84 3.959 0.103009 
sterol metabolism 53 0.48 21 0.99 0.1009775 
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Table 6. Dissection of genes regulated >2 fold in Wnt5a-/- calvarial cells as compared to wild type 
cell. The differentially expressed genes are ones that are overlapped among the resulting lists with three 
separate analytic methods as described in materials and methods. The fold changes (Wnt5a-/- /WT) were 
calculated based on the expression values which were obtained after background correction and loess 
normalization.  
Table 6.     
Dissection of genes altered >2 fold in Wnt5a-/- calvarial cells as compared to wild 
type cells 
average fold changes 
Gene Name 
Genbank 
accession # Up Down 
Cell cycle & cell cycle regulation    
transformed mouse 3T3 cell double minute 2 (Mdm2) NM_010786 3.12  
growth arrest and DNA-damage-inducible 45 gamma 
(Gadd45g) 
NM_011817 2.67  
annexin A1 (Anxa1) NM_010730 2.51  
retinoblastoma 1 (Rb1) NM_009029 2.5  
RB1-inducible coiled-coil 1 (Rb1cc1) NM_009826 2.47  
cyclin G (Ccng) NM_009831 2.43  
dual specificity phosphatase 1 (Dusp1) NM_013642 2.43  
Reprimo, TP53 dependant G2 arrest mediator candidate 
(Rprm) 
NM_023396 2.35  
forkhead box G1 (Foxg1) NM_008241 2.32  
cyclin-dependent kinase 6 (Cdk6) AK030810 2.25  
S100 calcium binding protein A6 (calcyclin)  NM_011313 2.22  
protein phosphatase 3 J05479 2.09  
insulin-like growth factor 2 (Igf2) NM_010514  -6.54 
mini chromosome maintenance deficient 6 (Mcmd6) NM_008567  -2.86 
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fibroblast growth factor 2 (Fgf2) NM_008006  -2.84 
transforming growth factor alpha (Tgfa) NM_031199  -2.83 
growth arrest specific 1 (Gas1) NM_008086  -2.76 
regulator of G-protein signaling 2 (Rgs2) NM_009061  -2.15 
cell division cycle 20 homolog AK075998  -2.12 
sestrin 2 (Ses2) BC005672  -2.05 
growth arrest specific 2 (Gas2)  NM_008087  -2.05 
mini chromosome maintenance deficient 2(Mcmd2) NM_008564  -2.02 
    
Cell proliferation & cell growth    
inhibin beta-A NM_008380 4.54  
caveolin, caveolae protein, 22 kDa (Cav) NM_007616 3.76  
insulin-like growth factor binding protein 7 (Igfbp7) NM_008048 3.35  
insulin-like growth factor 1 (Igf1) NM_010512 3.13  
heparin-binding EGF-like growth factor (Hbefg) NM_010415 2.86  
caveolin 2 (Cav2) AK004663 2.72  
fibroblast growth factor 9 (Fgf9) NM_013518 2.66  
annexin A1 (Anxa1) NM_010730 2.51  
COP9 (constitutive photomorphogenic) homolog, subunit 2 
(Cops2) 
NM_009939 2.24  
S100 calcium binding protein A6 (calcyclin) (S100a6) NM_011313 2.22  
cysteine rich protein 2 (Crip2) NM_024223 2.2  
interleukin 7 (Il7) NM_008371 2.16  
nerve growth factor, beta NM_013609 2.09  
epithelial membrane protein 1 (Emp1) NM_010128 2.06  
insulin-like growth factor 2 (Igf2) NM_010514  -6.54 
endothelial differentiation, sphingolipid G-protein-coupled 
receptor, 3 (Edg3) 
NM_010101  -3.53 
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insulin-like growth factor binding protein 4 (Igfbp4) NM_010517  -2.89 
fibroblast growth factor 2 (Fgf2) NM_008006  -2.84 
transforming growth factor alpha (Tgfa) NM_031199  -2.83 
nephroblastoma overexpressed gene (Nov) NM_010930  -2.81 
growth differentiation factor 10 (Gdf10) S82648  -2.6 
latent transforming growth factor beta binding protein 4 
(Ltbp4) 
AK009837  -2.39 
growth factor receptor bound protein 10 NM_010345  -2.37 
7-dehydrocholesterol reductase (Dhcr7) NM_007856  -2.26 
protease, serine, 11 (Igf binding) (Prss11) NM_019564  -2.17 
stem cell growth factor (Scgf) NM_009131  -2.01 
    
Skeletal development     
follistatin (Fst) NM_008046 5.49  
periostin, osteoblast specific factor NM_015784 3.22  
tissue inhibitor of metalloproteinase 3 (Timp3) NM_011595 3.19  
lysyl oxidase (Lox) NM_010728 2.44  
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 (Plod2) NM_011961 2.42  
integrin alpha 6 AK034186 2.37  
a disintegrin and metalloproteinase domain 9 (meltrin 
gamma) (Adam9) 
NM_007404 2.36  
BMP-binding endothelial regulator (Bmper) NM_028472 2.3  
procollagen, type IV, alpha 3 binding protein (Col4a3b) AK020301 2.1  
secreted phosphoprotein 1 (Spp1) NM_009263 2.09  
insulin-like growth factor 2 (Igf2) NM_010514  -6.54 
transforming growth factor, beta induced (Tgfbi) NM_009369  -6.16 
procollagen, type II, alpha 1 (Col2a1) NM_031163  -3.43 
a disintegrin-like and metalloprotease (reprolysin type) with AK040370  -2.9 
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thrombospondin type 1 motif, 2 (Adamts2) 
 insulin-like growth factor binding protein 4 (Igfbp4) NM_010517  -2.89 
growth-differentiation factor-10 (Gdf10) S82648  -2.6 
procollagen, type VII, alpha 1 (Col7a1) NM_007738  -2.49 
procollagen C-proteinase enhancer protein (Pcolce) NM_008788  -2.35 
hypothetical Fibronectin type III domain containing protein AK086582  -2.26 
procollagen, type XIV, alpha 1 AK009906  -2.12 
apolipoprotein E (Apoe) NM_009696  -2.09 
procollagen, type VI, alpha 1 (Col6a1) NM_009933  -2 
SPARC related modular calcium binding 1 (Smoc1) NM_022316  -3.67 
SPARC related modular calcium binding 2 (Smoc2) NM_022315  -3.23 
matrix gamma-carboxyglutamate (gla) protein BC009120  -2.08 
    
Genes involved in hedgehog signaling    
forkhead box G1 (Foxg1) NM_008241 2.32  
Desert hedgehog (Dhh) NM_007857  -17.08 
growth arrest specific 1 (Gas1) NM_008086  -2.76 
forkhead box C1 (FoxC1) NM_008592  -2.67 
forkhead box D1 (FoxD1) NM_008242  -2.61 
forkhead box C2 (FoxC2) NM_013519  -2.29 
patched domain containing 3 (Ptchd3) AK017136  (-1.69) 
    
Genes involved in Wnt signaling    
WNT1 inducible signaling pathway protein 1 (Wisp1) NM_018865 1.99  
secreted frizzled-related sequence protein 2 (Sfrp2) NM_009144  -2.72 
    
Regulation of transcription    
calcium-regulated heat-stable protein 1 (Carhsp1) NM_025821 6.05  
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neurotrophin 3 (Ntf3) NM_008742 2.73  
LIM and cysteine-rich domains 1 AK075847 2.65  
peroxisome proliferator activated receptor gamma (Pparg) NM_011146 2.63  
retinoblastoma 1 (Rb1) NM_009029 2.5  
forkhead box G1 (FoxG1) NM_008241 2.32  
transcription elongation factor A (SII)-like 8 (Tceal8) NM_025703 2.31  
carboxyl terminal LIM domain protein 1 (Pdlim1) NM_016861 2.29  
ubiquitin protein ligase E3A (Ube3a) NM_011668 2.26  
zinc finger protein 54 NM_011760 2.24  
COP9 (constitutive photomorphogenic) homolog, subunit 2 
(Cops2) 
NM_009939 2.24  
nuclear receptor subfamily 3, group C, member 1 (Nr3c1) NM_008173 2.09  
Sin3-associated polypeptide 18 (Sap18) NM_009119 2.04  
M.musculus Otx1 mRNA X68883  -6.3 
solute carrier family 4, sodium bicarbonate cotransporter-
like, member 10 
NM_033552  -3.46 
androgen receptor (Ar) NM_013476  -3.09 
mini chromosome maintenance deficient 6 (Mcmd6) NM_008567  -2.86 
forkhead box C1 (FoxC1) NM_008592  -2.67 
forkhead box D1 (FoxD1) NM_008242  -2.61 
sterol regulatory element binding protein 2 (Srebp2) AF374267  -2.43 
forkhead box C2 (FoxC2) NM_013519  -2.29 
glucocorticoid-induced leucine zipper (Gilz) NM_010286  -2.23 
nuclear receptor coactivator 3 (Ncoa3) NM_008679  -2.15 
paternally expressed 3 (Peg3) NM_008817  -2.07 
LIM only 4 (Lmo4) NM_010723  -2.06 
LIM homeobox transcription factor 1 beta (Lmx1b) NM_010725  -2.06 
mini chromosome maintenance deficient 2 (Mcmd2) NM_008564   -2.02 
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Table 7. Correlation analysis between the real-time PCR results and the microarray results. The 
fold change of the microarray data was based on the gene expression levels after background correction 
and normalization. Correlation coefficient was calculated with Pearson method.  
Table 7.    
Correlation analysis between real-time PCR results and microarray results 
Gene Symbol GB Acc. RT-PCR_fold Change Microarray_fold Change 
Ccng1 NM_009831 2 2.43 
Rb1 NM_009029 2.7 2.5 
Fst NM_008046 3.5 5.49 
Wisp1 NM_018865 1.3 1.99 
Sfrp2 NM_009144 -4.76 -2.72 
Runx2 NM_009820 -8.33 -1.14 
Osx NM_130458 -8 -1.02 
Col2a1 NM_031163 -10 -3.45 
Igf2 NM_010514 -12.5 -6.67 
Dhh NM_007857 -11.11 -17.24 
Correlation coefficient (r)  0.780937 
p-value     p=0.007 
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Table 8.  
Canonical Wnt signaling pathway related genes altered in Wnt5a-/- calvarial cells 
average fold 
changes Gene Name Genbank accession # Up Down 
WNT1 inducible signaling pathway protein 1 (Wisp1) NM_018865 1.988  
casein kinase 1, gamma 1 (Csnk1g1) AK018639 1.676  
protein phosphatase 1, catalytic subunit, beta isoform 
(Ppp1cb) AK004686 1.670  
adenomatosis polyposis coli (Apc) NM_007462 1.646  
solute carrier family 9 (sodium/hydrogen exchanger), 
isoform 3 regulator 1 (Slc9a3r1) NM_012030 1.480  
kringle containing transmembrane protein 1 (Kremen1) NM_032396 1.479  
glycogen synthase kinase 3 beta (Gsk3b) NM_019827 1.471  
dishevelled 2, dsh homolog (Dvl2) NM_007888 1.280  
casein kinase 1, alpha 1 (Csnk1a1) AK017353 1.276  
wingless-related MMTV integration site 7A (Wnt7a) NM_009527 1.243  
secreted frizzled-related sequence protein 2 (Sfrp2) NM_009144  -2.722
casein kinase II, alpha 1 polypeptide (Csnk2a1) NM_007788  -1.701
dickkopf homolog 3 (Dkk3) AK004853  -1.605
secreted frizzled-related sequence protein 4 (Sfrp4) NM_016687  -1.599
frizzled homolog 1 (Fzd1) NM_021457  -1.588
phosphatidic acid phosphatase type 2B (Ppap2b) NM_080555  -1.546
wingless-related MMTV integration site 16 (Wnt16) NM_053116  -1.486
frizzled homolog 5 (Fzd5) NM_022721  -1.481
transcription factor 3 (Tcf3) NM_009332  -1.381
transducin-like enhancer of split 3 (Tle3) NM_009389  -1.367
catenin beta interacting protein 1 (Ctnnbip1) NM_023465  -1.343
frizzled homolog 8 (Fzd8) NM_008058  -1.269
amino-terminal enhancer of split (Aes) NM_010347  -1.264
catenin (cadherin associated protein), beta 1, 88kDa 
(Ctnnb1) NM_007614  -1.262
Chorionic gonadotropin beta  NM_053189   -1.238
 
 85
Fig. 9. Expression of osteogenic, adipogenic and chondrogenic markers. Human MSCs were induced 
to differentiate along osteogenic, adipogenic and chondrogenic lineages by treatment with the 
corresponding induction media. Total RNAs were purified from the cells harvested after 1-14 days of 
induction (D1-D14), and cDNAs were synthesized. BSP (marker for osteogenesis), PPARg (marker for 
adipogenesis), and COL2A1 (marker for chondrogenesis) were amplified by PCR for 30 cycles. GAPDH 
was amplified for 25 cycles.  
D0       D1       D3        D7       D14
BSP:
PPARγ:
COL2A1: 
G3PDH: 
 
 
Fig. 10. WNT5A, WNT3, and WNT2b expression by differentiated hMSCs. A) Human MSCs were 
differentiated to osteogenic, adipogenic and chondrogenic lineages. GAPDH and WNT5A were amplified 
by PCR for 25 cycles. WNT3 and WNT2B were amplified for 35 cycles. 20 μl of PCR products were 
separated on 1% agarose gel, and visualized by exposure to UV light for 50 sec using LumiImager. These 
images are representative of results obtained in three separate trials using 3 donors. B) WNT (WNT5A, 
WNT2B and WNT3) gene expression was further quantified by real-time PCR, and normalized by the 
corresponding sample expression level of GAPDH. The relative PCR products of WNT5A (osteogenic 
(solid black), adipogenic (diagonal) and chondrogenic (white) differentiated hMSCs) was compared to 
those of un-differentiated hMSCs (grey). The expression level of WNT2B was very low (Ct = 34~36) and 
WNT3 expression was not detectable (not shown). 
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Fig. 11. hFZD5 expression during osteoblastic differentiation of hMSCs. Human MSCs were 
differentiated along osteogenic pathway for 0 to 14 days. Human FZD5 was amplified by PCR for 30 
cycles. GAPDH was amplified for 25 cycles. 20 μl of PCR products were separated on 1% agarose gel, 
and visualized by exposure to UV light (LumiImager). This result is representative of results obtained in 
three separate trials using 3 donors. 
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 Fig. 12. Cell proliferation and cell morphology were altered in Wnt5a-/- osteoprogenitor cells.  A) 
Mouse calvarial cells were obtained from Wnt5a-/-, Wnt5a+/-, and wild type mice. 5,000 of the passage one 
cells were seeded onto 12-well plate and cultured in MEM medium containing 10% FBS and antibiotics. 
After culturing for 5 days, the liquid crystal violet assay was performed. The optical density at 570 nm 
was measured and the average of five replicates was plotted. B) Cell morphologies of the cultured 
calvarial cells were visualized under microscope at 10x magnification. 
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Fig. 13. Real-time PCR evaluation of the gene expression level. The mRNA levels of the Wnt5a-/- mice 
calvarial cells were compared to those of the wild type cells. The experiments were repeated six times and 
the average fold changes after knocking down Wnt5a expression were plotted.  
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Discussion 
 
 This analysis of Wnt expression in osteoblastic differentiation of hMSCs demonstrated a 
possible role for Wnt5a in the early process of stem cell differentiation. The role of Wnt5a in 
osteogenic differentiation was supported by observations of Wnt5a expression in cultured 
hMSCs and was confirmed during in vivo hMSCs differentiation. Investigation of adipogenic, 
chondrogenic, and osteogenic differentiation suggests pathway-specific utilization of different 
Wnt signals. Both the high level of Wnt5a compared with other Wnts and the increased 
expression of Wnt5a associated with osteogenic differentiation in contrast to reduced levels in 
chondrogenesis, implicates its significance in osteoblastic functions.  
 The identification of mouse Wnt expression by the degenerate RT-PCR cloning from 
chimeric human mouse tissue formed during ectopic bone formation in the HA/TCP cubes was 
not surprising. The degenerate primers shared significant sequence homology with mouse Wnts. 
The inductive responses of the host following implantation of a tissue engineering construct 
should include growth and differentiation regulatory molecules such as Wnts. Beyond the Wnts 
identified in the human osteoblastic cells differentiated in vitro, mouse Wnt2 and mouse Wnt11 
were found and confirmed by sequence analysis in the in vivo forming bone tissue. The cellular 
source of their expression requires further identification. We hypothesize that Wnt2 and Wnt11 
expression occurs in early, infiltrating cells of the host within the tissue engineering constructs. 
These cells may be of hematopoietic origin and reflect general inflammatory response to implant 
surgery or more specific response to the implanted construct. Monkley et al has detected Wnt2 
expression in blood vessel cells and early heart tissues of mouse embryos. Wnt2 deficiency in 
mice resulted in vascular abnormalities including defective placental vasculature (Monkley et al 
1996). Wnt11, like Wnt5a, was reported to be a non-canonical Wnt. It functions in 
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cardinogenesis mediated by protein kinase C (PKC) and Jun amino-terminal kinase (JNK) 
(Pandur et al 2002). However, the roles of Wnt2 and Wnt11 in bone formation or tissue repair 
are undefined.   
The essential role of Wnt5a in skeletal development was underscored in the Wnt5a knockout 
mouse, which shows significantly shortened limb, absence of distal digits, and deformity of the 
developing face, including cleft palate, truncated snout, mandible and tongue, reduced growth of the 
external ear (Yamaguchi et al 1999; Yang et al 2003). Shortening of the long bone can result from at least 
three different underlying mechanisms, including a delay of chondrocyte differentiation (Vortkamp et al 
1996; Crowe Zikherman and Niswander 1999), a decrease in chondrocyte proliferation (Karp et al 2000), 
as well as defects in the osteoblastic differentiation (Ducy et al 1997; Komori et al 1997; Otto et al 1997). 
Decreased incorporation of 5-bromo-2’-deoxyuridine (BrdU) in the progress zone of the limb in Wnt5a-/- 
mice suggested the potential role of Wnt5a in regulating the proliferation of the mesenchymal progenitors 
(Yamaguchi et al 1999). Absent expression of Sry-related HMG box 9 (Sox9), the earliest marker for 
mesenchymal condensation, in the distal limb in Wnt5a-/- mice indicated that Wnt5a activity is required 
for mesenchymal condensation (Yang et al 2003). In vitro studies of chondrogenic differentiation 
indicated the negative role of Wnt5a (Chimal-Monroy et al 2002). Wnt5a misexpression in the chicken 
limb was found to delay the chondrocytes differentiation (Hartmann and Tabin 2000). Thicker cartilage 
and delayed chondrocyte hypertrophy in Col2a1-Wnt5a transgenic mice further suggested that Wnt5a 
delays chondrocyte differentiation (Yang et al 2003). In this study, the decreased expression pattern of 
Wnt5a during chondrogenic differentiation of hMSCs also suggested that Wnt5a could regulate 
chondrocyte differentiation.  
The overlapped expression pattern of Wnt5a and Runx2, and the reduced Runx2 
expression and absence of osteocalcin expression in Wnt5a-/- mice suggested the role of Wnt5a 
in osteoblast differentiation (Yang et al 2003). However, prior to this study, a specific role for 
Wnt5a in osteogenesis had not been determined. The presently observed expression pattern of 
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Wnt5a during osteogenic differentiation of hMSCs suggested a role for Wnt5a in osteoblastic 
differentiation. The decreased expression of Runx2, Osterix, and ALP in Wnt5a-/- mouse 
calverial cells further suggested that Wnt5a signaling is important during osteogenesis, and 
Wnt5a might act upstream of those key osteoblast transcription factors. This could have an 
indirect effect on the observed decreased proliferation of Wnt5a-/- calvarial cells. Wnt5a has been 
implicated in control of cell growth (Prockop Gregory and Spees 2003). Osteoprogenitors 
derived from Wnt5a-/- mice were senescent and showed reduced cell growth. Genes controlling 
cell cycle, cell division, cell cycle progression regulation, mitotic cell cycle, and cell 
proliferation were altered as suggested by the microarray results in this study.  
 Wnt5a is considered as a non-canonical Wnt that mediates downstream signaling through JNK or 
Ca2+/PKC. The MAPK signaling pathway was altered in Wnt5a deficient mouse calvarial cells, which 
suggests that Wnt5a signaling may influence the MAPK/JNK pathway. Further detailed investigation is 
required to ascertain this hypothesis. On the other hand, several components involved in Ca2+/PKC 
pathway were also regulated in Wnt5a-/- cells, such as phospholipase C, protein phosphatase 3, 
calcium/calmodulin-dependent protein kinase I gamma (Camk1g), Camk4, and PKC.  
 In addition, Wnt5a may affect the canonical Wnt signaling pathway. In the microarray study, at 
least 26 of the Wnt/β-catenin pathway involved genes were altered in Wnt5a deficient cells. It has been 
shown that Sfrp2 binds to canonical Wnts and inhibit β-catenin-mediated signaling (Galli et al 2006). In 
this study, Sfrp2 was shown to be downregulated when Wnt5a activity was diminished. It suggested that 
Wnt5a might antagonize canonical Wnt signaling, which has been demonstrated previously by other 
investigators (Ishitani et al 2003; Olson and Gibo 1998; Topol et al 2003; Torres et al 1996).    
 The hedgehog (Hh) family of genes, including sonic hedgehog (Shh), Indian hedgehog (Ihh), and 
desert hedgehog (Dhh), encode signaling molecules that regulate multiple functions during organ 
development and in adult tissues. Hh signal is mediated by binding to the thansmembrane receptor 
Patched. Upon binding to Hh, Patched releases its inhibition of Smoothened (Smo), which is then free to 
 92
transmit its signal downstream and consequently control of Gli family transcription factors. Fox family 
genes are known to be regulated by Hh signaling. They are the major mediators of the function of Hh 
signaling in craniofacial development (Jeong et al 2004). In the Wnt5a-/- cells, the levels of several genes 
involved in Hh signaling were altered. Included were Dhh, Gas1, FoxC1, FoxC2, FoxD1, FoxG1, Gli3 
and Gli5, suggesting some interaction between Hh signaling and Wnt5a signaling. Hh could be 
downstream target of Wnt5a signaling and requires further investigation. 
 In conclusion, Wnt5a expression occurs in lineage specific manner. Knock-out cells reveal Wnt5a 
expression affects cell cycle progression and is required for cell growth. The knock-out model also 
suggests a role for non-canonical Wnt (Wnt5a) signaling during osteogenesis.  
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CHAPTER IV 
 
Discussion 
 
 Mesenchymal stem cells (MSCs) from bone marrow are a source of 
osteoprogenitors. Under certain circumstances, MSCs differentiate into osteoblasts, 
chondrocytes, adipocytes, and myoblasts. The well controlled osteoblastic differentiation 
from the MSCs is essential in bone wound healing, treatment of osteogenesis imperfecta 
and other bone disease. It is believed that Runx2 and Osterix are the critical transcription 
factors that control the early stage of osteoblast differentiation (Ducy et al 1997; Komori 
et al 1997; Nakashima et al 2002a; Otto et al 1997; Skillington Choy and Derynck 2002). 
Recent investigations revealed the importance of Wnt signaling in control of stem niche 
and the lineage-specific differentiation of MSCs (Baksh and Tuan 2007; Gregory et al 
2005a; Gregory et al 2005b; Ross et al 2000). It has been shown that Wnt10b and Wnt1 
have the capacity to inhibit adipogenesis and promote osteochondrogenesis (Ross et al 
2000). On the other hand, Dkk1, an inhibitor of canonical Wnt signaling pathway, has 
been shown to predispose MSCs to cell cycle entry and inhibit osteogenesis (Gregory et 
al 2005a).     
 It is now well known that canonical Wnt signaling regulates osteoblastic 
differentiation demonstrated from a variety of in vivo and in vitro models (Bodine and 
Komm 2006; Glass and Karsenty 2007). In our study, osteoprogenitor cells 
overexpressing constitutive active LRP5 showed activated β-catenin signaling and 
enhanced osteoblast differentiation (Chapter II), which is similar to the reported effects of 
canonical Wnt signaling on osteogenesis. Wnt3a is known to regulate osteoblastogenesis 
and chondrogenesis by β-catenin mediated canonical Wnt signaling pathway from in 
vitro cell culture models (Derfoul et al 2004; Fischer Boland and Tuan 2002a; Nakashima 
et al 2002b). However, it is recently found that Wnt3a also activates G protein-linked 
PKCδ signaling and promotes bone formation (Tu et al 2007).     
 Compare to canonical Wnt signaling pathway, the involvement of non-canonical 
Wnt signaling pathway during stem cell proliferation and differentiation is not well 
understood. Chang et al. recently found that Wnt4 enhances osteogenic differentiation of 
MSCs in vitro and promotes bone formation in vivo. The activity of Wnt4 is dependent 
on p38 mitogen-activating protein kinase (MAPK) (Chang et al 2007). Wnt7b is found to 
induce osteogenesis via PKCδ-mediated signaling pathway and its function in 
soteogenesis is independent of β-catenin (Tu et al 2007). Wnt5a is known as a non-
canonical Wnt that can activate both JNK-mediated and PKC/Ca2+-mediated signaling 
pathways (Slusarski et al 1997; Yamanaka et al 2002). However, other studies show that 
Wnt5a also mediates canonical Wnt signaling pathway (Toyofuku et al 2000). The 
function of Wnt5a in bone development has been suggested from the knockout phenotype, 
which shows shortened long bone, missing distal digits, cleft palate, and defected 
craniofacial development (Yamaguchi et al 1999; Yang et al 2003) Our study (Chapter III) 
showed that genes regulating osteogenesis, such as Runx2, Osterix, ALP, and BMP antagonists 
are downregulated in Wnt5a-/- calvarial cells, which suggested a role of Wnt5a in osteogenesis. 
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Wnt5a may affect the cell proliferation or differentiation by targeting those osteogenic genes. The 
regulated genes involving cell cycle and the noted cell growth deficiency in Wnt5a-/- calvarial 
cells suggested that Wnt5a is necessary during cell proliferation. It is recently published by Baksh 
et al. that treatment of hMSCs with Wnt5a conditioned medium promoted osteoblast 
differentiation measured by ALP activity and mineralization, without affecting cell proliferation. 
Interestingly, they found that suppression of canonical Wnt sigaling enhanced the effects of 
Wnt5a on promotion of osgeogenesis (Baksh Boland and Tuan 2007).   
 What is the communication between canonical Wnt signals and non-canonical Wnt 
signals? It is previously shown that Wnt5a has the capacity to antagonitze the canonical Wnt 
pathway by promoting the degradation of β-catenin, and thus downregulation of the target 
transcription factors (Topol et al 2003). Baksh et al. recently showed the similar effect of Wnt5a 
on Wnt3a-mediated canonical pathway, and the inhibition effect of canonical Wnt signaling 
pathway on Wnt5a-mediated cellular phenotype (Baksh Boland and Tuan 2007). However, the 
detailed cross-talk between canonical and non-canonical Wnt signaling is well understood. 
Recent review paper on calcium pathway suggested that its antagonism of Wnt/β-catenin 
signaling may through Ca++ release and/or the nuclear factor of activated T cells (NFAT) 
transcription factor (Slusarski and Pelegri 2007).     
 How do Wnt signaling pathways integrate with other signaling pathways that play 
important roles in osteoblastogenesis? One of these signals is the members of BMP family 
proteins. Our study (Chapter II) demonstrated that canonical Wnt signal affects SMAD3/4-
mediated transcription in a BMP2-dependent manner. The positive effect of BMP2 on canonical 
Wnt signaling pathway could be direct or indirect. BMP2 treatment has been shown to induce 
expression of Wnt ligands and receptors, and consequently activates β-catenin/LEF-mediated 
transcription (Chen et al 2007; Fischer Boland and Tuan 2002b). Secondly, it has been suggested 
that SMAD3/4 directly interact with β-catenin/LEF1 resulting in transcriptional activation of the 
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LEF1-responsive promoters (Labbe Letamendia and Attisano 2000; Nishita et al 2000). On the 
other hand, β-catenin signaling is crucial for BMP2- induced new bone formation. Mice 
expression conditional β-catenin null alleles display inhibited osteogenesis and chondrogenesis 
induced by BMP2 (Chen et al 2007).      
 Another signal that may interact with Wnt signaling is hedgehog pathway. Hedgehog and 
canonical Wnts signals and responses are similar in many resprects, and has been considered as 
sister pathways (Lum and Beachy 2004). The observed dramatic change of Dhh expression in 
Wnt5a-/- cells suggested possible cross-talk between Wnt5a-mediated signaling pathway and 
hedgehog signaling pathway. In vivo and in vitro analysis by Hu et al. has suggested that Ihh may 
function upstream and in concert with canonical Wnt signaling pathway during 
osgeoblastogenesis in long bones (Hu et al 2005). However, studies regarding the communication 
between Wnt and Hedgehog signals are very limited, requiring further study investigation.              
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